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Prognostic factors predicting survival in patients with high-
grade osteosarcoma located in the extremity or trunk
S. Bielack, B. Kempf-Bielack, G. Delling, U. Heise, K. Helmke,
T. Huf, H. Jürgens, M. Kevric, R. Kotz, S. Lang & A. Zoubek, for
the Cooperative OsteoSarcoma Study Group COSS
(Dept. of Ped. Hematology/Oncology, University Muenster, Germany)
Introduction: An analysis was performed in order to determine
which  of  the  prospectively  collected  variables  included  in  the
COSS-database might correlate with survival in osteosarcoma.
Patients and methods: All 1702 patients with previously untreated
(except primary surgery) high-grade osteosarcoma of the extremity
or trunk registered into a neoadjuvant COSS-study before 7/98
were included. Factors analyzed by  Kaplan–Meier  analysis and
Cox-regression were patient age (1648 <; 54 x ‡  40 years) and sex
(1007 male; 695 female), tumor site (1595 limb; 107 axial; for
limbs: 240 proximal; 1355 distal), tumor size (1037 <; 523 ‡  1/3 of
involved bone, data available for extremity tumors only), primary
metastases (1491 no; 211 yes), osteosarcoma as first (1670) or sec-
ondary (32) malignancy, lag-time before diagnostic biopsy (576 <;
560  ‡  70 days), time from biopsy to therapy (1524  £ ; 178 > 3
weeks), timing of surgery (157 primary; 1451 delayed), type of sur-
gery  (881  ablative;  720  limb-salvage),  response  to  preoperative
chemotherapy (734 good (<10% viable tumor); 586 poor), and
best  surgical  remission  (1510  macroscopically  complete;  180
incomplete).
Results: At  last-follow-up,  1160  of  1702  patients  were  alive
(median follow-up 5.5 years for survivors; range, 9 days–19.0
years). Actuarial 5, 10, and 15 year survival rates were 65.3%,
59.8%,  and  57.3%,  respectively.  In  univariate  analyses,  age
(actuarial survival: young 57.7%, old 41.6%), site (appendicular
59.0%, axial 29.3%; for extremity tumors: distal 61.2%, proxi-
mal 47.1%), size (small 64.7%, large 48.6%), primary metas-
tases  (no  61.6%,  yes  26.7%),  response  (good  72.6%,  poor
43.1%), and surgical remission (yes 60.1%, no 10.9%) were sig-
nificant prognostic factors. All factors but age kept their signifi-
cance in multivariate testing, with surgical remission, response
and primary metastases showing the highest odds ratios. Except
for a few irradiated patients, long-term survival without com-
plete  surgery  of  all  lesions  was  almost  exclusively  limited  to
patients with presumed primary metastases which lacked histo-
logical proof.
Conclusion: Primary metastases, tumor site and size are prog-
nostic factors which can be used to risk-stratify osteosarcoma
patients  at  diagnosis.  A  realistic  assessment  of  an  individual
patient’s  prognosis,  however,  can  only  be  made  later  in  the
course  of  treatment,  when  information  on  surgical  remission
and response to chemotherapy can be included into the calcula-
tion.
Supported by Deutsche Krebshilfe
Prolonged  follow-up  of  extremity  osteosarcoma.  Results
from the European Osteosarcoma Intergroup
J.S. Whelan, S. Weeden, B. Uscinska  & A. McTiernan for the
European Osteosarcoma Intergroup (EOI)
Study aims: To describe the results of two large randomised trials
of neo-adjuvant chemotherapy for extremity osteosarcoma (OS)
after prolonged follow up.
Background: Reported survival rates for extremity OS range from
50 to over 70%. The best results have been reported from single
centres  or  from  non-randomised  studies  but  these  results  are
potentially subject to significant bias. To minimise such bias, the
EOI  has  conducted  large  multicentre  randomised  studies  of
chemotherapy for OS. The first two studies have been analysed
with  94%  of the participants  having been followed to death or
beyond 5 years.
Methods: In the first study patients were randomised to receive
the combination of doxorubicin and cisplatin with or without the
addition of high-dose methotrexate. The second study compared
doxorubicin and cisplatin to a multiagent  regimen  given for 42
weeks based on the T10 programme.
Subjects: One hundred and seventy-nine patients were treated in
the first study with either the two- or three-drug combination. In
the second study, 391 patients were randomised. The median age
was 16 (range 3-40). Sites of disease were femur, 315 (55%), tibia/
fibula, 177 (31%) and upper limb, 78 (14%). Three hundred and
seventy-three patients underwent limb salvage surgery. Data avail-
able from 332 patients showed > 90% histological necrosis in 30%.
Median follow-up of these 570 patients is 9.6 years.
Results: Overall 5-year survival was 56% (95% CI 52–60%) and
progression-free  survival  was  44%.  Those  with  tibia/fibula
tumours,  treated  by  limb  salvage,  or  with  good  histological
response had improved survival. There were no differences based
on trial, treatment, age or sex. First recurrence was local in 4%,
lung only in 33%, bone in 4% and a combination in 10%. First
recurrence after 5 years occurred in four patients (3%).
Conclusion: These data, from large multicentre trials, provide the
firmest evidence of outcome for extremity OS. Future randomised
studies must aim to improve survival towards that reported in open
studies.
Low  grade  central  osteosarcoma—fibrous  dysplasia  and
parosteal subtype: a study of 28 cases of the Hamburg Bone
Tumor Registry
C. Engels, M. Werner & G. Delling
(Abteilung  Osteopathologie/Pathologisches  Institut/Universität
Hamburg)
Aim:  The  central  osteosarcoma  is  regarded  as  a  high  grade
malignant  tumor,  whereas  the  low  grade  central  osteosarcoma
(LGCO) appears to be a distinct member of this group which is
characterized  by  a  more  favorable  clinical  outcome  than106 Abstracts
conventional osteosarcoma. LGCOs represent less than 2% of all
osteosarcomas.  Morphologically  it  is  simulating  benign  bone
tumors  (fibrous  dysplasia,  nonossifying  fibroma,  desmoplastic
fibroma, chondromyxoid fibroma), tumor-like lesions (aneursymal
bone cyst) or parosteal osteosarcoma. Only a small number of this
rare  tumor  has  been  described  so  far.  Clinical  data  and
radiographic and histological features of 28 LGCOs were studied.
Methods: We have investigated 28 cases of LGCO (18 parosteal
and 10 fibrous dysplasia-like subtype) regarding their age distribu-
tion, localization, radiological and histological features, in some
cases their clinical course.
Results: The age distribution was broad (range 8–65 years). The
primary symptom was pain, mean duration lasting 6 months. The
median follow up after surgery spanning 46 months. Most cases of
the parosteal subtype were treated by wide resection (n=11). Only
one case recurred 6 months after marginal resection and developed
lung metastases 15 months later. Within fibrous dysplasia subtype
4, recurrences could be identified after three intralesional curretage
and one wide resection. Another case manifested three additional
local recurrences and developed three consecutive lung metastases
with  only  minor  transformation  into  a  higher  grade  tumor.  At
present no patient has died of his disease. Radiologically the paro-
steal subtype was more sclerotic and mainly localized in the distal
femur. The fibrous dysplasia subtype was more lytic and was found
in different sites of the skeleton. Despite a morphological pattern of
fibrous dysplasia or parosteal osteosarcoma they histologically show
spindle-shaped  cells  with  minimal  hyperchromatic  and irregular
nuclei. In 14 cases (50%) benign tumor or high grade malignancy
was supposed by the consultant pathologist.
Conclusions: The knowledge of different subtypes  of low grade
central osteosarcoma supports and substantiates a correct diagno-
sis and enables a good clinical outcome by surgery alone if at least
wide margins are used.
Supported by the Deutsche Krebshilfe
Osteosarcoma over the age of 40
R.J. Grimer on behalf of the European Musculoskeletal Oncology
Society
(The  Royal  Orthopaedic  Hospital  Oncology  Service,  Bristol  Road
South, Birmingham, UK)
Purpose: To ascertain whether patients over the age of 40 have a
different disease pattern and prognosis to younger patients with
osteosarcoma.
Background: Osteosarcoma is principally a disease of adolescents
but 13% of all patients with osteosarcoma will be over the age of
40—and to date have been excluded from most national trials of
treatment of osteosarcoma. A collaborative study from EMSOS
has collected data on these patients.
Material: Data on 486 patients have been contributed from 13
centres. The ages ranged from 40 to 89 with a mean of 54. Two
hundred and seventy-five were male and 211 female. The most
common sites were femur followed by pelvis and tibia and 84 had
a secondary osteosarcoma—42 related to Paget’s disease and 42
secondary to radiation. Thirty patients had ‘low grade’ osteosar-
coma, the remainder having high grade tumours of which 57 had
metastases at presentation. Almost half the patients had chemo-
therapy Surgery consisted of amputation in 118 and limb salvage
surgery in 252, with  113  having endoprostheses and 15  having
allografts. One hundred and eighty-four were felt to have had ade-
quate surgical margins and 102 had close or inadeqaute margins.
Eighty-five patients had radiotherapy of which 41 were palliative.
Results: The overall survival rates were 37% at 5 years falling to
27% at 10 years. The 5- and 10-year survival rates for stages 1, 2
and 3 tumours were, respectively: 78 and 62%; 41 and 28%; 9 and
9%. Patients over the age of 60 and patients who did not have ade-
quate treatment not surprisingly fared worse, as did all patients with
secondary osteosarcoma.  The  median  survival  time  for  patients
with Paget’s osteosarcoma was 7 months and for radiation sarcoma
was 12 months. For patients with stage 2 tumours the effect of age
was such that the 5-year survival rates were 45% for those less than
60 and 28% for those over 60. There was little information about
effectiveness of chemotherapy but there was a trend for those with
a good response to fare better than those without. Local recurrence
arose in 7% of those having amputations and 22% of those having
limb salvage surgery. It was closely related to margins of excision,
with  27%  of  those  having  inadequate margins  developing  local
recurrence compared to 12% of those with adequate margins.
Conclusion: Osteosarcoma  over  the  age  of  40  requires  just  as
much care and multidisciplinary working as osteosarcoma in the
younger age group. Patients with secondary osteosarcoma have a
dismal outlook. Chemotherapy and effective surgery remain the
mainstay of treatment.
Local relapses in osteosarcoma patients: the experience of
the French Society Of Pediatric Oncology (SFOP)
E. Mascard1, P. Violas2, R. Kohler2, J. Dubousset1, N. Dupouy3,
L. Brugières3, C. Rodary3 & C. Kalifa3
(1Hopital St Vincent de Paul, Paris, 2Hôpital Edouard Herriot, Lyon,
3Institut Gustave Roussy, Villejuif, France)
Study  aim: To  study  the  incidence  and the  outcome  of  local
relapses in children treated for an osteosarcoma
Methods: We reviewed data of children registered in the SFOP
OS97  prospective  study  for  a  newly  diagnosed  osteosarcoma.
Patients were treated with pre-operative chemotherapy combining
high-dose  methotrexate  (HDMTX) 8–12  g/m2 and adriamycin.
After surgery, good responders (GR) (less than 10% viable cells)
received additional HDMTX and adriamycin, and bad responders
a combination of ifosfamide, cis-platinum and vindesine.
Subjects: Two hundred and one patients  were included in the
study from 1987 and 1994: there were 104 good responders and
95 bad responders; 166 patients underwent a conservative surgery.
Results: A local relapse occurred in 16 patients (10% of the con-
servative surgery): 5 GR and 11 BR. All these local relapses were the
first site of relapse and occurred with a median delay from diagnosis
of 18 months (6–42 months). Nine of 16 patients are alive with no
evidence  of  disease  (including  four  patients  who  subsequently
developed lung metastasis) with a median follow-up of 41 months
after relapse. Seven patients died (median delay: 12 months).
Conclusion: The occurrence of a local relapse after conservative
treatment of an osteosarcoma is not always fatal. A second remis-
sion and a long-term survival can be achieved by immediate ampu-
tation  and  appropriate  second  line  chemotherapy.  We  are
currently conducting the same study for the patients included in
the on-going study of the SFOP (OS94 study). One hundred and
ninety-seven have been included so far and the incidence and out-
come of local relapse in these patients will be presented.
Local  recurrence  of  osteosarcoma:  survival  rate  and
management
H. Katagiri, S.R. Cannon, T.W.R. Briggs, J. Cobb & J. Witt
(London Bone Tumour Service, Royal National Orthopaedic Hospital,
Middlesex, UK)
Purpose: To assess the clinical features, development of metas-
tases and survival rate of patients with local recurrence after the
resection of osteosarcoma in a large series.
Patients and methods: Five hundred and thirty patients with high-
grade osteosarcomas were treated between 1989 and 1998. Fifty-
four patients (10%) developed local recurrence after resection and
adjuvant chemotherapy. There were 38 men and 16 women with aAbstracts 107
mean age of 19 years (range 6–50). The mean follow-up was 39
months (range 7–120 months). The vast majority had clear resec-
tion margins. Histological response was category 1 in 27% of the
patients, and category 2 in 73%. Clinical features, treatment, and
prognosis were analysed. Survival rates were examined using Kap-
lan–Meier Analysis.
Results: The average interval between the first resection and local
recurrence  was  15  months  (range  2–109  months).  Forty-one
patients (76%) had local recurrence in deep soft tissue, seven in
bone, and six in subcutaneous tissue. Twenty-six patients (49%)
had  lung  metastasis  at  the  time  of  local  recurrence,  whilst  21
patients  (38%)  developed  it  later.  Thirty  patients  (57%)  were
treated with resection of the recurrent lesion and 18 (32%) were
treated with amputation. One-, 3- and 5-year survival rates after
local recurrence were 0.57, 0.38, and 0.22, respectively.
Conclusion: (1) 87% of patients with local recurrence developed
metastases either concurrently or at a later date. Immediate ampu-
tation did achieve local tumour control. However, the survival rate
was not statistically higher; (2) 87% of the local recurrence arise in
soft tissue. Therefore, careful attention should be paid to secure the
wide margin around biopsy tract, muscle insertion to the affected
bone, and neurovascular bundle at the time of initial resection.
Prognosis after recurrence of osteosarcoma. A COSS report
on 547 patients with relapse following complete remission
B. Kempf-Bielack1, D. Branscheid, S. Flege, M. Kevric, R. Maas,
H. Jürgens, & S. Bielack for the Cooperative OsteoSarcoma Study
Group COSS.
(1Department of Pediatric Hematology/Oncology, University Muenster,
Germany)
Introduction: The COSS-database was used to evaluate the prog-
nosis after osteosarcoma relapse and to determine whether prog-
nostic factors influencing survival post-relapse might be identified.
Patients  and  methods: Among  all  patients  with  previously
untreated high-grade osteosarcoma of the extremity or trunk regis-
tered into a neoadjuvant COSS-study before 7/98, 547 patients
relapsed  after  having  previously  achieved  a  complete  surgical
remission.  These were evaluated for patient-  and tumor-related
characteristics identifiable at time of relapse which might influence
post-relapse survival.
Results: The median interval from diagnosis of osteosarcoma to
relapse was short at 1.5 (0.1–10.3) years. One hundred and nine-
teen relapses were detected in the first, 242 in the second, 108 in
the third, 36 in the fourth, 18 in the fifth year, and only 24 later.
Median follow-up post-relapse was 1.0 year for all patients and 1.8
(0–17.3) years for 174 survivors. Three hundred and seventy-three
patients  died,  359  of  osteosarcoma,  11  of  other  and  three  of
unknown causes. Actuarial survival at 2,  5, and 10  years post-
relapse was 34.4, 20.6, and 15.1%. Survival post-relapse did not
correlate significantly with patient age or sex, the former site or size
of  the  primary  tumor,  whether  primary  metastases  had  been
present, or with tumor response to first-line chemotherapy. The
probability to survive increased with increasing time between diag-
nosis  and relapse  (5-year  survival  9.2%  if  interval  <  1.5  years;
32.1% if ‡  1.5 years). Five-year survival was 30.8% for 34 patients
with isolated local recurrences and 21.3% for 481 patients with
metastases only, but only 3.5% for 32 patients with combined local
and systemic  recurrences. Metastases  involved the  lung in  444
(355 as only site of relapse: 5-year survival 24.3%), distant bones
in 88 (44 bone only: 23.6%) and other sites in 54 patients (11 other
sites  only:  20.0%).  Five-year  survival  was  dismal  at  4.8%  for
patients  with involvement of more than one system  (local/lung/
bone/other), compared to 24.5% if only one system was involved.
Conclusion: Survival  following  osteosarcoma  relapse  remains
poor. Risk factors pointing to a high relapse risk  after frontline
therapy  are  generally  unsuitable  to  predict  outcome  following
relapse. A short latency period between diagnosis and recurrence
and involvement of multiple locations at relapse identify a popula-
tion with particularly unsatisfactory results.
Supported by Deutsche Krebshilfe
Post relapse survival in 159 patients with osteosarcoma of
the extremity
S. Ferrari, A. Briccoli, S. Rimondini, M. Mercuri, P. Picci, A.
Tienghi1, A. Brach Del Prever2, A. Comandone3 & G. Bacci
(Dipartimento  di  Oncologia  Muscolo-Scheletrica  Istituto  Ortopedico
Rizzoli; 1Oncologia Medica Ravenna; 2Clinica Pediatrica Università
di Torino; 3Oncologia Medica Ospedale, Gradenigo Torino, Italy)
An analysis of prognostic factors for survival was performed in 159
patients  with  osteosarcoma of the  extremity who relapsed from
1986 to 1997. They had received a combined treatment with sur-
gery of the primary lesion and neoadjuvant chemotherapy deliv-
ered according to four protocols based on high-dose methotrexate,
doxorubicin, cisplatin and standard dose ifosfamide. The median
relapse-free interval (RFI) was 23.6 months (1.9–98.3 months).
One hundred and twenty-three (77%) patients relapsed only with
lung metastases (monolateral 77, bilateral 46; median number of
lung nodules, 3), 36 (23%) patients had recurrence also in other
sites; 111 (70%) patients were free of disease after adequate surgi-
cal treatment; 85 (53%) patients received a second line chemother-
apy  treatment,  based on  high-dose  Ifosfamide  (15  g/m2,  5-day
continuous infusion) in 50 (59%) of them. The estimated 5-year
survival after relapse (S) was 27.5%. Univariate analysis identified
the site of relapse (lung 5-year S 32%, other 12%, p < 0.003), RFI
(£  24 months 5-year S 13%, > 24 months 5-year S 46%, p < 0.001),
the site of lung metastases (monolateral 5-year S 37%, bilateral
17%, p < 0.001) and the number of lung metastases (£  2 nodules
5-year S 57%, > 2 nodules 5-year S 10%, p < 0.0001) as predictive
factors for S. Chemotherapy offered a significant advantage only in
patients with > 2 pulmonary nodules ( with chemotherapy 5-year
S 17 %, without chemotherapy 5-year S 0%, p = 0.002), whereas
no significant differences were seen in patients with one/two pul-
monary nodules (42 vs. 62%, p = 0.46). A longer survival time and
a higher 5-year S was seen in patients with other than lung metas-
tases  who received chemotherapy (with  chemotherapy 5-year S
22%, without chemotherapy 5-year S 0%, p = 0.002). In a multi-
variate analysis including only patients with lung metastases the
number of nodules (£  2 nodules RR 0.3, 95% CI 0.15–0.49, p <
0.0001)  and  RFI  (£   24  months  RR  2.18,  95%  CI  1.3–3.7,
p < 0.005) were predictive factors for S. About 25% of patients
with recurrent osteosarcoma can be rescued. Lung location, a >
24-month relapse-free interval, £  2 pulmonary nodules are positive
predictive factors which identify patients who can be treated with
surgery only. More than two pulmonary nodules and other than
lung location identify poor risk patients who can have benefit from
chemotherapy.
Radiation induced bone sarcoma: a review of the EMSOS
database
H. Patterson & J.S. Whelan on behalf of EMSOS
Data were sought from six centres; 65 patients (31 male and 34
female) were identified who satisfied the criteria for the diagnosis
of radiation induced bone sarcoma. The median age at diagnosis
of the condition for which the patient received their radiotherapy
was 20 years (range 3 months to 66 years), and the most frequent
diagnoses were Ewing’s sarcoma (13 patients), giant cell tumour
(eight patients), breast cancer (seven patients), Hodgkin’s lym-
phoma (five patients),  retinoblastoma  (four patients)  and pri-
mary  bone  lymphoma  (three  patients).  The  median  age  at108 Abstracts
development of the radiation induce bone sarcoma was 33 years
(range 4–78 years) following a median latency of onset of 116
months  (range  45–389  months).  The  radiation  dose  varied
between 12 and 70 Gy, with a median of 47 Gy. The histological
diagnosis of the radiation-induced bone sarcoma was osteosar-
coma in 40 patients, MFH in 10 patients, fibrosarcoma in nine
patients and sarcoma NOS in the remaining six patients. With a
median  follow-up  of  23  months  (range  2–208  months),  24
patients are reported to be alive and disease free, 35 patients have
died of their  radiation-induced tumour, two patients  are alive
with disease, one patient has died of unrelated causes, and three
patients have been lost to follow-up. Of the 24 patients who are
alive  and  well,  median  follow-up  54  months  (range  8–208
months) 12 patients underwent amputation, four patients had a
claviculectomy, six patients underwent endoprosthetic replace-
ment, one patient had a craniofacial excision and one patient had
a  marginal  hemi-vertebrectomy.  Seventeen  patients  received
combination chemotherapy based on combinations of doxoru-
bicin,  cisplatin,  methotrexate  and ifosfamide,  including  10/12
patients who underwent conservative surgery, median follow-up
57.5 months (range 17–208 months).
Conclusion: Complete surgical excision in the absence of meta-
static disease carries the best prognosis for patients with radiation-
induced bone sarcoma. However, salvage appears possible for a
proportion of patients who undergo more conservative surgery in
conjunction with combination chemotherapy.
Secondary malignancy following therapy for sarcoma in the
COSS, CWS, or CESS studies
S. Bielack, T. Pilz, B. Fröhlich, B. Kempf-Bielack, S. Ahrens, E.
Koscielniak, M. Kevric, M. Paulussen, W. Schwager, J. Treuner &
H. Jürgens
(Depts. of Pediatric Hematology/Oncology, University Muenster and
Olgahospital Stuttgart, Germany)
Introduction: The databases of the cooperative soft tissue sarcoma
(CWS), Ewing’s sarcoma ((EI)CESS), and osteosarcoma (COSS)
studies were combined in order to learn more about secondary
malignancy after treatment for sarcoma.
Patients and methods: All patients with sarcomas entered into any
neoadjuvant study of  the  aforementioned groups  prior  to 1998
were evaluated for the subsequent development of secondary can-
cers.  Affected  patients  were  analyzed for  patient-,  tumor-,  and
therapy-related variables, as well as outcome.
Results: Follow-up information was available for 5176 patients, of
whom 1996 had been followed >5, 618 >10 , and 103 >15 years.
Sixty-two secondary cancers were identified, four in patients with
multiple  malignancies. The median age at diagnosis of sarcoma
had  been  11  (0.3–53)  years;  histology,  osteo-  20,  rhabdo-  18,
Ewing’s  18,  other  sarcoma  six.  Treatment  had  included
chemotherapy in 61, radiation in 32, and surgery in 51. Secondary
malignancies were 33 hematological neoplasms (ANLL/MDS 25,
ALL/NHL seven, Hodgkin’s disease one) a median of 42 (5–113)
months after sarcoma and 29 solid tumors (second sarcoma 12,
carcinoma 10, brain tumor five, melanoma one, germ cell tumor
one) after 82 (13–177) months. The cumulative risk to develop
any secondary malignancy (hematological/solid) was 0.8% (0.6/
0.2%) at 5  years, 3.2%  (1.8/1.5%) at 10  years and 6.6%  (2.0/
4.7%)  at  15  years.  Among  patients  with  secondary  cancers,
hematological  neoplasms  were  more  frequent  after  Ewing’s
sarcoma,  after  metastatic  disease,  after  multiple  cytostatic
therapies  or  high-dose  chemotherapy,  and  after
epipodophyllotoxins. At least  two-thirds  of the 24  solid  tumors
following  bone  and  soft  tissue  sarcomas  other  than  Ewing’s
belonged to cancers associated with the Li–Fraumeni syndrome.
Actuarial survival at 2 and 5 years from diagnosis of secondary
cancer was 48 and 38%. At last follow-up, 29 affected patients
survived (20 in complete remission of all malignancies) and 30 had
died  at  a  median  of  6  (0–79)  months  after  diagnosis  of  the
secondary malignancy (26 due to secondary malignancy, three due
to original sarcoma, one due to yet another malignancy), three
patients  were without  follow-up. Prognosis  was  better  for  solid
tumors than for hematological neoplasms.
Conclusion: Secondary malignancies constitute a relevant but not
universally fatal threat to patients with sarcoma. Both induction
and individual predisposition seem to contribute to their develop-
ment.
Supported by Deutsche Krebshilfe & EU-Biomed
The role of radiotherapy in ccombination with surgery in 66
Ewing’s
M.  San-Julián,  J.L.  Barroso,  J,  Vasquez,  Azinovic,  L.
Sierrasesúmaga & J. Cañadell
(Dpto.  Traumatología,  Clínica  Universitaria,  Avda.  Pio  XII,  36,
31008 Pamplona, Spain)
Aim: To evaluate the role of radiotherapy in combination with
surgery in 66 Ewing’s sarcomas completely treated at our institu-
tion between 1981 and 1997.
Methods: The  protocol  of  treatment  consisted  in  preoperative
chemo- and radiotherapy (3000–5900 rads), conservative surgery
and intraoperative radiotherapy, and postoperative chemotherapy
during 1 year. The mean interval between biopsy and surgery was
5 months (1–21). The minimum follow-up was 2 years (2–19).
Results: 100% of necrosis or only focii of viable cells were found
in 51/66 of cases when comparing with 3/21 patients treated at
other institutions with different protocols, who came to our centre
after detection of recurrences. Despite the number of ‘inadequate’
surgical margins (31), only two local recurrences were found in this
series (one of them after previous surgery with wrong diagnosis and
the other one after insufficient resection and poor necrosis. Com-
plications (nerve palsy, skin necrosis fractures, deformities) due to
the use of radiotherapy were found, but only two of these cases
required amputation 63% are alive at a mean follow-up of 9 years.
Conclusion: Taking into account the number of axial location (17
cases), the difficulties in resection, and the volume of the majority of
these tumours, the combination of chemo- and radiotherapy, may
improve the possibilities of conservative surgery and the survival rate.
Pelvic Ewing tumors (ET)—the impact of surgery
R.W.  Rödl1,  Ch.  Hoffmann1,  N.  Lindner1,  H.  Jürgens2  &
W. Winkelmann1
(Departments  of  1Orthopedics  and  2Department  of  Pediatric
Hematology  and  Onkology,  Westfälische  Wilhelms  Universtät,
Münster, Germany)
Objective: Local  therapy  of  pelvic  Ewing’s  tumors  (ET)  has
remained a challenge due to its central localization and the usually
large tumor volumes. The impact of surgery for event-free survival
is still discussed.
Method: 38  patients  underwent  wide  resection  of  pelvic  ET
between 1981 and 1996 in a single institution. Chemotherapy was
administered  according  to  the  appropriate  EI/CESS  protocols.
Radiotherapy was added in 36  of 38  patients.  The outcome of
these patients were compared to all patients (n=113) of the EI/
CESS—study who underwent radiotherapy for local tumor control
between 1981 and 1996. Both groups were comparable regarding
tumor volume. Fifty-nine of 113 radiated patients had metastases
at diagnoses compared to 11 of 38 patients, who underwent sur-
gery. Event-free survival curves were estimated according to the
Kaplan–Meier method. The log rank test was used to compare the
survival curves of both groups.Abstracts 109
Results: Mean  follow-up  was  69  month  in  both  groups.  Two
patients developed local recurrence after surgery (5%) compared to
25 patients (22%) of the radiotherapy group. The event-free sur-
vival rate was 39%  with  surgery  and 25%  without surgery (p =
0.0532). According to the subgroup of localized pelvic ET, event-
free survival rate was 43% with surgery and 28% without surgery (p
= 0.1171). Pelvic tumors with metastases at diagnoses show no dif-
ference according to local therapy (27 and 23% estimated survival).
Conclusion: Wide resection of pelvic ET improves local control
significantly. Better local tumor control, performing tumor resec-
tion, shows a trend towards better event-free survival. More effec-
tive  systemic  treatment  is  needed for metastatic  patients  before
they may benefit from surgery. Surgery has to be considered for
local therapy in localized pelvic ET.
Local  control in  Ewing  tumours of bone. A report of the
(European  Intergroup)  Cooperative  Ewing’s  Sarcoma
Studies
M. Paulussen1, S. Ahrens1, G. Amann2, J. Dunst2, U. Exner2, B.
Fröhlich1, R. Kotz2, A. Schuck2, W. Winkelmann2, A. Zoubek2 &
H. Jürgens1
(Departments of 1Paediatric Haematology and 2Oncology, University
of Münster, Münster, Germany)
Introduction: Local  recurrence  represents  a  major  obstacle
towards cure for most sarcoma patients. Local control was ana-
lysed for Ewing tumour patients registered in the German/Conti-
nental (EI)CESS database.
Patients and Methods: On May 1st, 1999, 672 patients with local-
ised Ewing tumours of bone were registered in the three consecu-
tive studies CESS 81 (n=95), CESS 86 (n=213), and EICESS 92
(n=364). Four hundred and six patients (60%) were male; median
age was 14 (range, <1–35) years. Primary tumour sites were: pelvic
(n=145, 22%), other trunk (n=179, 27%), femur (n=127, 19%),
or  other  extremity  (n=215,  32%)  (incomplete  data  in  three
patients). All patients  received neoadjuvant systemic  multiagent
chemotherapy and local therapy by surgery (n=145, 23%), radio-
therapy  (n=151,  24%),  or  combined  surgery  and  radiotherapy
(n=332, 53%) (incomplete data in 44 patients). Local control was
assessed by means of competing risk analyses, event-free survival
(EFS) was computed according to Kaplan and Meier. Compari-
sons between groups were done by c 2- or logrank-tests.
Results: After a median time under study of 93 (range, 1–222)
months, 5-year EFS was 0.61. The probability of local (including
combined local plus distant) failure (LOCFAIL) was 0.11. Local
control has improved more recently: CESS 81, LOCFAIL 0.25,
CESS  86,  0.09,  EICESS  92,  0.08;  p<0.01.  Pelvic  (LOCFAIL
0.17) or other central axis sites (0.15) bear a higher risk of local
failure than femur (0.04) or other extremity (0.08) sites, p<0.01.
Local failures were less common when surgery was part of the local
therapy  strategy:  LOCFAIL  surgery,  0.04,  radiotherapy,  0.28,
combined surgery plus radiotherapy, 0.07; p<0.01.
Conclusion: Local  control  in  Ewing  tumours  is  sufficient  with
modern  local  therapy.  Complete  surgical  resection  should  be
attempted where feasible, and eventually be supplemented by radio-
therapy.
Supported by Deutsche Krebshilfe,  EU  Biomed, and  Sabrina  Forsc-
hungsfond e.V.
The  role  of  radiotherapy  in  multimodality  treatment  of
Ewing’s sarcoma
A. Cassoni, J. Whelan & A. McTiernan
(University College London Hospitals, London, UK)
Material and methods: Between 1990 and 1999, 83 patients with
Ewing’s/PNET tumours were treated by radiotherapy with radical
intent as part of multimodality therapy as the only local therapy
(48), or as an adjuvant to surgery (35). Their median age was 18
years (range 5–54); minimum follow-up is 6 months. Primary sites
include  pelvis  25;  lower  limb  30;  chest  wall  five;  spine  five.
Twenty-one had metastases  at presentation. Doses  of radiation
were 55 Gy as sole therapy, 45 Gy as adjuvant (but doses to spinal
cord, heart and large volumes of lung were limited). In 69 a hyper-
fractionated  regimen,  concurrent with  chemotherapy,  was  used
(twice daily 1.6-Gy fractions with planned gaps); in the remainder
conventional once daily treatment in 1.8–2-Gy fractions
Results: There was failure of local control in six of those treated with
adjuvant radiotherapy; all were concurrent with or, preceded by, dis-
tant progression and all these patients are dead. A further seven have
died without evidence of local relapse. Of the 48 with radiotherapy as
the sole local therapy, 14 had failure of local control. In nine this was
within 6 months and associated with progression elsewhere. All these
patients are dead. Five patients experienced late and, initially, iso-
lated local relapses 10, 25, 58, 60 and 24 months after radiotherapy.
Three of these have died 24, 22, and 16 months after local relapse. A
further 14 have died without evidence of local relapse. The overall
control rate is 83% in the adjuvant group (overall survival of group
63%) and 71% in the sole local therapy group (OS 56%).
Local recurrence after treatment of Ewing’s sarcoma
A. Abudu & R.J. Grimer
(The  Royal  Orthopaedic  Hospital  Oncology  Service,  Bristol  Road
South, Birmingham B31 2AP, UK)
Purpose: To  ascertain  the  prognosis  and  significance  of  local
recurrence following treatment of Ewing’ sarcoma.
Material: 300 patients with non-metastatic Ewing’s sarcoma have
been treated since 1975. Of these, 25 have developed local recur-
rence at some time in the course of their disease.
Results: Of the 30 patients, 15 had undergone surgical treatment
and 10  radiotherapy alone. All  had received chemotherapy. The
most common site for local recurrence was in the pelvis, followed by
the proximal femur. The time to LR averaged 19 months, but was
only 14 months in those treated by radiotherapy alone whilst was 26
months in those treated surgically. In four cases the LR was the first
evidence of recurrent disease, whilst in a further 13 cases further dis-
ease was discovered either at the time of restaging or within a few
months. The LR was treated by further chemotherapy and radio-
therapy  in  most  cases  but  two  underwent amputation.  Original
treatment, response to chemotherapy and type of surgery made no
significant difference on the outcome of LR. In patients with previ-
ous or synchronous metastases, all were dead in a further 14 months
(median survival 5 months), whilst in those without metastases at
the time of restaging there was a 28% chance of survival at 4 years.
Conclusion: LR in Ewing’s is bad news. Most will have metastases
develop within a short time and will succumb to this recurrent dis-
ease. In this series there were no patients with late isolated LR fol-
lowing previous radiotherapy. Control of the LR can usually be
achieved with  further radiotherapy, treatment  of the  metastases
requires systemic treatment but finding this form of effective treat-
ment is proving difficult.
Preliminary results of the EICESS 92 study
H.  Jurgens1,  S.  Ahrens1,  B.  Frohlich1,  M.  Paulussen1,  A.
Zoubek2,  R.  Kotz2,  G.  Amann2,  I.  Lewis2,  P.A.  Voûte2,  W.
Winkelmann2, B. Dockhorn-Dworniczak2 & A.W. Craft2
(Departments of 1Paediatric Haematology and 2Oncology, University
Children’s Hospital, Munster, Germany)110 Abstracts
The disease-free survival for patients with primary Ewing tumours
of bone has impressively improved with the introduction of sys-
temic chemotherapy in addition to local control with surgery and/
or radiation. EICESS 92, a project of the German (GPOH) and
British (UKCCSG) societies for paediatric oncology, has stratified
treatment  in  standard  risk  (SR)  and  high  risk  (HR)  based  on
tumour  volume  (</_100  ml).  SR  patients  were  randomised  for
cyclophosphamide (CYC)- versus ifosfamide (IFO)-based mainte-
nance following induction with vincristine, actinomycin D, ifosfa-
mide, and adriamycin (VAIA). HR patients were randomised for
VAIA  versus the  addition of etoposide (EVAIA). The trial was
open from July 1992 until November 1999. A total of 470 protocol
patients with localised disease and no visible metastases at diagno-
sis  were  recruited:  SR,  147  patients;  HR,  323  patients.  The
median age was 15 years, ranging from 8 months to 35 years, the
female/male ratio was 1:1.5. The median time since diagnosis was
46 months, ranging from 3 to 88 months. On 15 November 1999
the estimated EFS at 5 years was 63% for the total group, and 75%
for SR and 58% for HR patients. With respect to randomisation,
the 5-year EFS for SR patients was 71% for VACA and 79% for
VAIA (p=0.37). In HR patients the results were 54% for VAIA and
62%  for  EVAIA  (p=0.60).  Regarding  local  therapy,  75%  of
patients underwent surgery, 24% surgery alone and 51% in com-
bination  with  either  pre-  or  postoperative  radiation;  23%  of
patients received definitive radiation. EFS at 5 years according to
local therapy was 67% for surgery with or without radiation, and
54% for definitive radiation. The local failure rate was 3.6% for the
total group, 2.3% for patients with surgery +/– radiotherapy, and
8.4% for patients with definitive radiation. Regarding response to
treatment  in  HR  patients,  the  proportion  of  good  histological
response (<10% viable tumour) was 72% following VAIA and 80%
following EVAIA (p=0.20). No secondary malignant neoplasms
have been reported so far in this cohort of patients. To date, the
results according to randomisation have not yielded statistical sig-
nificance. Longer follow-up is needed to draw definitive conclu-
sions. Surgery is superior in comparison to radiation to assure safe
local control.
With support by Deutsche Krebshilfe (M43/92/Jü2), EC-BIOMED 1
(BMH1-CT92-1341), EC-BIOMED 2 (BMH4-98-3956)
Limb-salvage surgery in Ewing’s sarcoma of childhood: 20
years experience at Istituto Ortopedico Rizzoli
M. Manfrini, M. Mercuri, P. Rosito1, E. Barbieri2, S. Giacomini,
L. Campanacci & G.Bacci
(Istituto  Ortopedico  Rizzoli,  1Clinica  Pediatrica  and  2Istituto  di
Radioterapia, Bologna, Italy)
In the period 1978–1997, 71 children affected by non-metastatic
Ewing sarcoma of bone were surgically treated at Istituto Orto-
pedico Rizzoli. There were 35 female and 36 male patients, all
under 13 years of age (mean age 8.2 years). All patients received
chemotherapy according to the different historic protocols. A limb-
salvage approach was preferred in 58 cases (82%), 37 of whom had
a skeletal reconstruction. Rotation-plasty was performed in four
patients  (5%),  while  the  remaining  nine  cases  were  amputated
(13%). Local radiotherapy was delivered in eight children (in three
patients before and in five patients after surgery). Surgical indica-
tions  changed along the  years. Classic amputations represented
21% (5/24) of surgical treatments during the first decade 1978–87,
while in the latter one (1988–97) they decreased to 8% (4/47). An
opposite trend was seen both in rotation-plasties (from 0 to 8%)
and limb-salvage surgeries (from 79 to 84%). In the 37 cases where
the bone was reconstructed, the tumor was localized mainly in dia-
physeal  femur  (10  cases),  proximal  femur  (six)  and  proximal
humerus (seven) followed by diaphyseal tibia (four), pelvic bones
(four), proximal tibia (two), distal femur (one), diaphyseal (one)
and  distal  radius  (one),  first  metatarsus  (one).  Reconstructive
techniques as well have improved in the last 20 years: in the period
1978–87  the  most  common  reconstruction  was  represented  by
artificial implants (77%), while in the next decade, the main surgi-
cal  group  was  that  of  biological  reconstructions  (85%).  Three
patients presented a local recurrence at a mean time of 43 months
after surgery (range 10–62 months). In a girl treated by resection
of the fibula plus radiation therapy, a treatment related sarcoma
appeared after 72 months. At a mean time of 85 months (range
25–241 months) from surgery, two cases were lost to follow-up, 50
patients were continuously disease free (70%), 14 died of disease
and five were alive after treatment of a relapse (one local, four dis-
tant). In reconstructed patients, 43% needed secondary surgery
because  of  septic  or  mechanical  complications;  four  children
(11%)  underwent  amputation  for  deep  local  infection.  In  the
reconstructed group, 32 patients with more than a 5-year follow-
up were available for functional evaluation according MSTS: 72%
presented a satisfactory result (excellent or good), 16% fair, and
12% poor.
Long-term follow up of Ewing’s sarcoma patients
F. Mittermayer, M. Sluga, R. Windhager1, P. Krepler, S. Lang, H.
Heinzl, M. Dominkus & R. Kotz
(Department of Orthopaedics, University of Vienna, Währinger Gürtel
18–20,  A-1090  Vienna,  Austria  and  1Department of Orthopaedics,
University of Graz, Austria)
This study analyses significant prognostic factors, interdisciplinary
approach and development of therapy of Ewing’s sarcoma patients
over the  last  three decades. Between 1/1949  and 12/1994,  140
patients  with  Ewing’s  sarcoma  were  treated  at  our  institution.
Median  follow-up  was  8.5  years.  Age  at  the  time  of  diagnosis
ranged between 1 and 51 years (mean 16 years). Fifty-one tumors
were located within the trunk and 89 within the extremities; 21
patients had preoperative metastases; 55 patients were treated in
the period between 1949 and 1980 (group 1), 85 patients between
1980 and 1994 (group 2). Patients in group 1 were either treated
without  (n=5)  or  with  polychemotherapy  (n=47).  Patients  in
group 2 were treated by CESS (n=50) or EICESS (n=35) chemo-
therapy.  In  group  1,  23  patients  underwent  only  biopsy,  32
patients  had  definitive  surgical  treatment,  48  patients  received
either only or additional radiation therapy. In group 2, the respec-
tive numbers of patients were: seven, 78, 43. Five-year overall sur-
vival increased from 27  to 57%,  5-year MFS from 25  to 59%.
Univariate independent significant prognostic factors on overall
survival were preoperative metastases (p=0.0001), tumor localisa-
tion (p=0.0048), type of chemotherapy (p=0.002) and response to
chemotherapy (p=0.0004). In multivariat analyses the develope-
ment  of  chemotherapy  (p=0.037)  was  evaluated  as  significant
factor for survival, furthermore tumor localisation (p=0.0017) and
metastases at diagnosis (p=0.0025). Systemic therapy rather than
type  of  local  treatment  seems  to  influence  the  overall  survival.
There was no significance found either in univariate or in multivar-
iate analyses in radiation therapy and/or surgical treatment.
A single centre experience of an intensive induction therapy
(VIDE) including stem cell collection for Ewing’s family of
tumours (EFT)
S.J.  Strauss,  A.  McTiernan,  D.  Driver,  M.  Hall-Craggs,  A.
Sandison, A.M. Cassoni, A.M. Kilby, M. Michelagnoli, J. Pringle,
J. Cobb, J. Witt, S. Cannon, T. Briggs & J.S. Whelan
(The London Bone and Soft Tissue Tumour Service, The Middlesex
Hospital, Mortimer Street, London W1N 8AA, UK)
Aim: To examine the feasibility,  tolerability and toxicity of an
intensified  induction  regimen  (VIDE)  in  patients  with  newlyAbstracts 111
diagnosed EFT; to assess ability to maintain dose intensity, and
predictability of peripheral blood stem cell mobilisation.
Patients and methods: Thirty patients, 10 with metastatic disease
at diagnosis, were treated with vincristine 1.4 mg/m2 (max. 2 mg)
on day 1, doxorubicin 20 mg/m2, ifosfamide 3 g/m2 + mesna, and
etoposide 150 mg/m2 on days 1–3. Cycles were given every 21 days
for up to six cycles. Patients with localised disease received further
chemotherapy with vincristine 1.4 mg/m2 on day 1, actinomycin
0.75 mg/m2 and ifosfamide 3 g/m2 on days 1 and 2 (up to eight
cycles). Those with metastatic disease at diagnosis were considered
for high dose therapy with busulphan (600 mg/m2) and melphalan
(140 mg/m2) with stem cell rescue. Treatment response was eval-
uated  clinically  and radiologically.  On  completion  of  induction
therapy, surgery or radiotherapy was undertaken.
Results: The median age was 17 years (7–36). One hundred and
seventy cycles of VIDE were given. The median treatment interval
was 21 days (21–60) and nadir count, Hb 8.3 (6.3–11.9), neu-
trophils 0.045 (0.0–2.1) and platelets 45 (3–343). Grade 3–4 neu-
tropenia  was  seen  in  97%  of  cycles  and  grade  3–4
thrombocytopaenia in 54%. There were 103 episodes of febrile
neutropenia  (61%).  Growth  factor  support  reduced  infectious
complications by 33%. Treatment interval was maintained in 80%
of cycles. Ifosfamide dose was maintained in 97% and doxorubicin
dose maintained in 98% of cycles. Etoposide dose was reduced, or
omitted,  in  24%  of  cycles.  Four  patients  did  not  complete  six
cycles due to unacceptable toxicity and one patient progressed on
treatment. Twenty patients underwent peripheral blood stem cell
harvesting, all successfully, 15 after cycle 3, and five after cycle 4.
Median CD34 yield was 3.6 ´  106/kg (0.1–14.5). Overall response
to  treatment,  measured  in  21  patients,  was  86%.  Histological
response was measured in 11 patients undergoing surgery, with
seven patients (64%) achieving > 90% necrosis of tumour.
Conclusion: VIDE is an effective induction regimen with substan-
tial but acceptable toxicity that allows predictable mobilisation of
stem cells in all patients. Maintenance of dose intensity is feasible
in the majority of patients for six cycles, and treatment interval sus-
tainable. Growth factors play a role in maintaining dose intensity
and reduce the rate of infectious complications.
A phase II study of docetaxel for the treatment of recurrent
osteosarcoma and Ewing’s tumours
J.S. Whelan & A. McTiernan
(London  Bone  and  Soft  Tissue  Tumour  Service,  The  Middlesex
Hospital, London, UK)
Study  aims: To  determine  the  response  to  and  toxicity  of
Docetaxel in (a) recurrent osteosarcoma and related spindle cell
tumours  of  bone  (OS)  and  (b)  recurrent  round  cell  tumours
(Ewing’s  tumours  and  primitive  neuroectodermal
tumours—EFT).
Background: Better  systemic  therapies  are required to improve
survival from OS and EFT. However few new active agents have
been  identified.  The  taxanes,  taxol  and docetaxel,  have  shown
important  activity, alone  and in  combination,  in other  diseases
such as breast, ovarian and lung cancer but their value in OS and
EFT is unknown.
Subjects and methods: Eligibility  criteria included a histological
diagnosis of EFT or OS, measurable progressive or recurrent dis-
ease after chemotherapy and normal liver function. Docetaxel 100
mg/m2 was given as a 1-h infusion every 3 weeks. Response was
assessed after every two cycles to a maximum of six. Nine patients
with osteosarcoma and one with MFH were treated. All except
one had extremity tumours treated by surgery. Eight had received
initial chemotherapy with doxorubicin and cisplatin, one with the
addition of ifosfamide and one a multiagent regimen. Five had
been  treated  with  second  line  chemotherapy  before  receiving
Docetaxel. Nine had lung metastases  and one intra-abdominal
disease.  Fourteen  patients  with  EFT  were  treated.  Three  had
extraosseous primaries.  Six  had other chemotherapy at  relapse
before docetaxel. Five had received high dose therapy.
Results: Patients  received a median of two cycles  (range 1–6).
There  were  no  responses  in  patients  with  OS.  A  single  partial
remission was seen in EFT (response rate 7%). One other patient
had  stable  disease.  A  total  of  61  cycles  were  given.  Toxicity
included alopecia and myelosuppression. Grade 3/4 infection was
uncommon when growth factors were used.
Conclusion: Docetaxel does not appear to have major activity as a
single agent in this heavily pre-treated group of patients with recur-
rent OS and EFT. Window studies should be considered in EFT
and  the  combination  of  docetaxel  and  cisplatin  or  carboplatin
could be investigated in OS.
Treatment of soft tissue sarcomas across a region
J. Glencross2, P. Silcocks3 & M.H. Robinson1
(1YCR  Department  of  Clinical  Oncology,  Weston  Park  Hospital,
2Leicestershire Health Authority, 3Trent Cancer Registry, Weston Park
Hospital)
Background: Bone and soft tissue sarcomas are a rare and heter-
ogeneous group of tumours, rarely seen by most clinicians during
their careers. Early recognition, appropriate and timely investiga-
tions, and treatment are shown to markedly affect outcomes. In
Trent Region a soft tissue sarcoma interest group had developed
outline consensus based guidelines for investigation and manage-
ment. The Trent Cancer Registry was asked to undertake a retro-
spective baseline audit of the care of such patients in Trent.
Findings: Soft tissue sarcomas registered with Trent Cancer Reg-
istry in 1995–1997 and meeting ICD-O criteria for site and mor-
phology were selected. Data were collected from clinical records
against a set of criteria outlined in the protocol in all registering
hospitals. Data included: recording of clinical details, specialties
involved  in  management,  diagnostic  and staging  investigations,
completeness  of surgery, histological  reporting,  use of  adjuvant
therapy and outcome (death or known recurrence). From 257 reg-
istrations, 204 cases were included: 10% of notes were unobtaina-
ble;  50%  were  initially  referred  to  general  surgeons,  although
definitive surgery was performed by surgeons (40%) and orthopae-
dic surgeons (33%); 74% saw an oncologist; 55% had a diagnostic
CT or MRI scan. Only 52% had adequate staging investigations;
63% had a biopsy; but 13% were ‘shelled out’ at biopsy. Thirty-
five percent had wide or adequate excision; in 48% primary surgery
was  incomplete  or  marginal.  Outcome  was  poorer  in  these
patients. Histological reporting was variable. No consistent grad-
ing system was used; details on tumour margins were available for
66% of cases; tumour size stated in 73% of cases; 52% received
adjuvant therapy; 10% being considered for EORTC trial entry.
Follow up was generally be a specialist oncology team, although
10% had no recorded follow up.
Conclusions: The audit demonstrates that optimal care as defined
by the soft tissue sarcoma group in Trent was not provided over
this period within the region. All clinicians should follow manage-
ment guidelines and proposals to set up specialist referral centres
should be considered.
Limb salvage surgery for soft tissue sarcomas of the hands
and feet
R.  Capanna,  P.  Caldora,  D.A.  Campanacci,  G.  Beltrami,  M.
Ceruso, M. Innocenti, L. Frazzetta & P. Olmi1
(C.T.O. and 1Radioterapia, Firenze, Italy)
Soft  tissue  sarcomas  arising  in  the  hand–wrist  and  foot–ankle
regions  are  frequently  extracompartmental.  In  these  locations,112 Abstracts
adequate surgical margins can only be obtained by the sacrifice of
several anatomical structures, including skin, tendons, vessels, and
nerves,  therefore  amputation  has  always  to  be  considered  as  a
treatment. However, by the use of microsurgical and plastic surgi-
cal techniques and of advanced reconstructive procedures, limb
salvage with wide surgical margins is  feasible in many patients.
Moreover, sarcomas in these sites have often a superficial location
and their diameter is frequently <5 cm, both being considered as
favorable prognostic features. This series includes 51 patients with
a soft tissue sarcoma of the hand (12), wrist (nine), foot (21), and
ankle (nine) operated in the last decade. Tumors were high-grade
lesions in 43 cases, and low-grade lesions in eight cases, and all but
two cases had an extracompartmental presentation. The diameter
of the primary tumor was <5 cm in 43 cases, and >5 cm in eight
cases. The lesion was primary in five cases, recurrent in 14 cases,
while a radicalization of a previous inadequate surgery was done in
32 cases. Five patients (10%) were amputated, whereas limb sal-
vage surgery was feasible in the remaining 47 cases. Of these, 43
cases had wide margins, three marginal margins, and one intra-
lesional margins. Either rotational (nine) or free (33) flaps were
required for reconstruction in 42 cases. Muscular transposition or
tendon grafts were used in 12 cases, nerve grafts in two cases, joint
arthrodesis in four cases, osteoarticular allografts in one case, and
an  index–pro-thumb  transposition  in  one  case.  At  an  average
follow-up of 60 months (4–153), 37 patients were continuously
disease-free  (72.5%), five had local recurrences (10%), and 13
developed metastases (25%). In our experience, soft tissue sarco-
mas of the hands and feet could be treated by limb salvage surgery
in 90% of the cases, whereas secondary amputation due to local
recurrence was needed in three cases (6%).
Bone  marrow  analysis  by  RT-PCR  of  newly  diagnosed
Ewing tumour patients: a prognostic factor?
B.  Fröhlich1,  S.  Ahrens1,  M.  Paulussen1,  H.  Jürgens1  &  B.
Dockhorn-Dworniczak2
(Departments of 1Paediatric Oncology and  2Pathology, University of
Münster, Münster, Germany)
Study and aim: More than 98% of Ewing tumours (ET) are char-
acterised by a translocation of chromosome 22, leading to an EWS/
ets-oncogene fusion. In recent studies bone marrow (BM) positiv-
ity  detected  by  reverse  transcriptase-polymerase  chain  reaction
(RT-PCR) has been considered as an adverse prognostic factor for
event free survival (EFS). Furthermore the chimeric transcript 7/6
has been proposed to be associated with a better clinical outcome
than other transcription factors.
Patients and methods: Between 04/1993 and 04/1998, newly diag-
nosed ET of 100 patients (patients) were analysed for Ewing-spe-
cific  rearrangements.  BM  was  available  for  RT-PCR  in  62
patients: 34/62 patients with localised ET, 28/62 patients with pri-
mary metastatic ET. Results are demonstrated by Kaplan–Meier
analysis.
Results: BM positivity was detected in 11/31 (32%) patients with
localised disease and in 23/28 (82%) patients with primary metas-
tastic ET. In localised ET, EFS 4 years after diagnosis is 0.80 in
patients without RT-PCR BM contamination and 0.71 in those
with  BM  involvement  (p=0.5241).  Five  primary  metastatic
patients who had no RT-PCR BM contamination showed an EFS
3 years after diagnosis of 0.67, compared to 0.19 in patients with
BM positivity (p=0.0088). Subgroup analysis according to type of
chimeric transcript shows, that there is no significant difference in
outcome between ET fusion transcript 7/6 compared to other ET
transcripatients:  4-year EFS  is  0.50  in  both, ET  with  chimeric
transcript 7/6 and ET with other transcripts (p=0.6771).
Conclusions: At present there is no evidence for an independent
prognostic impact of RT-PCR BM positivity in localised ET. The
type of chimeric transcript does not seem to correlate with out-
come. Prospective studies in larger groups of patients are needed
to fully evaluate the prognostic significance of molecular findings
in ET.
Supported by Deutsche Krebshilfe Grant M 43/92/Jü 2, EC BIOMED
1 and 2 Grants BMH1-CT92-1341 and BMH 4-98-3956,  and the
Sabrina Forschungsfond e.V.
Soluble Fas-antigen  (SFAS) in the serum of bone tumour
patients
N. Kushlinsky1, S. Abbasova2, Yu. Solovyev1, I. Kostanyan2, I.
Babkina1, A. Izgorodin3, V. Lipkin2 & N. Trapeznikov1
(1Russian  N.N.Blokhin  Cancer  Research  Centre  RAMS;
2M.M.Shemyakin  &  Yu.V.Ovtchinnikov  Institute  of  Bioorganic
Chemistry RAS; 3N.N.Burdenko Main Military Clinical Hospital of
the Ministry of Defence of RF, Russia)
Apoptosis is one of the important physiological processes which
disturbances underlie many pathological states including tumour
formation. We  have developed a sandwich-type enzyme-immu-
noassay test system for quantitative determination of one of the key
receptors triggering cellular apoptosis (Fas-Fas/APO-1/CD95) in
the blood serum of practically healthy people and bone tumour
patients (sFas). A comparative analysis of sFas incidence and levels
in these two groups was performed. Eighteen positive hybrids that
reacted with Fas were received, and nine most active clones were
selected for further experiments. Antibodies were produced in the
ascitic  fluid of 8-week-old BALB/c mice.  Full-size  recombinant
baculoviral Fas (‘Coultronics’, France) was used as the antigen.
The characteristics of the obtained antibodies included the follow-
ing steps: determination of the classes and subclasses of immu-
noglobulins, the types of their light chains, measurement of the
association constants of antigen–antibody complexes, and evalua-
tion of the possibility of applying the antibodies received for West-
ern blot analysis. The lower limit of sensitivity of the developed
system comprised 0.52 ng/ml. Serum samples of 108 bone tumour
patients  (aged  16–67  years)  were  studied:  osteosarcoma  (45),
chondrosarcoma (25), Ewing tumour (12), giant-cell tumour (12),
malignant fibrous histiocytoma (14); benign and tumour-like bone
lesions (osteochondroma, one; osteoblastoma four; chondroblast-
oma two; anevrismal bone cyst, three); mechanical bone traumas
(18). Control group consisted of 116 practically healthy people of
comparative age (65  men and 40  women). sFas  was more  fre-
quently found in the serum of oateosarcoma (85.7%) and Ewing
tumour  (100%)  patients  than  in  the  serum  of  healthy  people
(36%).  The  mean  levels  of  sFas  were  higher  in  osteosarcoma
(3.72±0.89 ng/ml), Ewing tumour (8.32±3.35 ng/ml) and chond-
rosarcoma (4.31±1.09 ng/ml) patients than in the control group
(0.86±0.30  ng/ml)  and  in  patients  with  mechanical  traumas
(2.62±0.50 ng/ml). Possible clinical value of sFas and its associa-
tion with disease pathogenesis and common biochemical and clin-
ico-morphological criteria of prognosis in bone tumour patients is
discussed.
Assessment  of  the  role  of  macrophage  osteoclast
differentiation in the pathogenesis of tumour osteolysis
T.T. Yang, A. Sabokbar, C.M.L. Gibbons & N.A. Athanasou
(Nuffield  Orthopaedic  Centre,  University  of  Oxford,  Oxford  OX3
7LD, UK)
Osteolysis is a major complication of both benign and malignant
tumours that arise in bone. The cellular mechanisms that account
for such bone destruction are poorly understood. Osteoclasts are
specialized bone-resorbing cells which effect the bone resorption
associated with tumour osteolysis. It has recently been shown thatAbstracts 113
tissue macrophages are capable of differentiating into bone-resorb-
ing  osteoclastic  cells  and  that  macrophage  colony-stimulating
factor (M-CSF) and osteoprotegerin ligand (OPGL), an osteob-
last-associated factor, are required for this to occur. The main aims
of this study were to determine: (i) whether macrophages isolated
from benign and malignant mesenchymal tumours are capable of
osteoclast formation and bone resorption; and (ii) the cellular and
humoral requirements for this to occur. Macrophages were iso-
lated from two soft tissue tumours, a malignant fibrous histiocy-
toma of the thigh  and a benign schwannoma of the  saphenous
nerve.  (Extraskeletal  mesenchymal  tumours  rather  than  bone
tumours were studied to avoid possible contamination by osteo-
clasts). Macrophage cultures were incubated on glass coverslips
and  dentine  slices  which  had  been  previously  seeded  with
UMR106 osteoblast-like cells. A total of 1´ 105 macrophages were
added to each well and the co-cultures maintained in the presence
of 1,25(OH)2D3, dexamethasone and M-CSF for up to 21 days.
Macrophages were also incubated in the absence of UMR106 cells
but in the presence of OPGL and M-CSF. Osteoclast formation in
these co-cultures was assessed for expression of osteoclast markers,
i.e., TRAP and lacunar bone resorption. Macrophages isolated
from both tumours, when co-cultured with UMR106 cells in the
presence  of  1,25(OH)2D3,  dexamethasone  and  M-CSF,  were
capable of differentiation into osteoclasts as determined by the for-
mation of TRAP-positive multinucleated cells and lacunar resopr-
tion  pit  formation.  Osteoclasts  also  formed  in  the  presence  of
OPGL and M-CSF alone. No evidence of TRAP expression or lac-
unar resorption was seen when UMR106 cells, OPGL or M-CSF
were omitted from macrophage cultures. The results of this study
show that macrophages present in benign and malignant mesen-
chymal tumours are capable of osteoclast differentiation and that
both M-CSF and OPGL (expressed on the surface of osteoblasts)
are required for this  to occur. As  reactive macrophages form a
major cellular component of most benign and malignant tumours
of bone, macrophage–osteoclast differentiation is likely to play a
significant role in tumour osteolysis.
Giant  cell  tumor  of  bone:  new  approaches  to  further
characterize the neoplastic cell origin
M. Wülling, M. Werner, G. Delling & E. Kaiser
(Abteilung  Osteopathologie/Zentrum  für  Biomechanik,  Universität
Hamburg, Hamburg, Germany)
Aims: The giant cell tumor of bone (GCT) is a locally destructive
tumor with a high rate of recurrence. Its frequency is 5% of all
bone. Histologically the GCT consist of at least three different cell
types. The neoplastic, mononuclear cell  that  is hypothesized to
attract  a  second  mononuclear  cell,  the  CD14+ monocyte. The
third cell component is the characteristic osteoclast-like, multinu-
clear giant cell, which forms from the attracted monocytes through
tumor-induced cell fusion. The origin of the neoplastic mononu-
clear cell has not been elucidated. In an attempt to further charac-
terize the nature of the neoplastic component of GCT we utilize
mesenchymal and osteoblastic differentiation markers.
Methods: Histological diagnosis of five GCT was performed by
two specialised pathologist (M. Werner, G. Delling). All three cell
types were harvested from representative tumor areas and cultured
for further studies. Cells from passages 0–3 were fixed on cover-
slips  for  immunocytochemical  evaluation  using  the  APAAP
method.
Results: The  expression  of  vimentin,  SH2,  SH3,  SH4  and
CD166  antigens was observed in all  neoplastic  cells of the five
GCT. The surface markers SH2, SH3, SH4, CD166, Stro1, stem
cell factor and alkaline phosphatase are expressed on bone marrow
stromal cells during osteoblastic differentiation. While the SH2,
SH3, SH4 and CD166 antigens are characteristic for the rare mes-
enchymal stem cell, the markers Stro1 and alkaline phosphatase
occur in more differentiated osteoblast precursors. However, none
of the stromal cells were positive for the Stro1-antigen, alkaline
phosphatase, stem cell factor nor its receptor c-kit. Also, these neo-
plastic cells showed no histiocytic markers like CD68 and CD14.
Conclusion: Based on these data, we suggest that the neoplastic
component of GCT originates from the undifferentiated mesen-
chymal stem cell population, which occurs in a frequency of 0.1%
in normal adult bone marrow.
This  work  was  supported  by  the  Deutsche  Forschungsgemeinschaft,
GK476.
A new P53 germline mutation in a Li-Fraumeni family that
induces chemoresistence to doxorubicin
L. Sangiorgi1, M.A. Cerone2, S. Soddu2, G. Gobbi1, E. Lucarelli1,
A. Brach del Prever3, P. Picci1 & L.J. Helman4
(1Rizzoli  Orthopedic  Institute,  Bologna,  2Regina  Elena  Cancer
Institute, Rome, 3University of Turin, Turin, Italy, and 4NCI, NIH,
Bethesda, MD, USA)
A phenotypic Li-Fraumeni  family  (mother died of breast  carci-
noma at the age of 35, brother died of rabdomyosarcoma at the age
of 3, two sisters died of osteosarcoma at the ages of 10 and 14) was
investigated for the presence of germline p53 mutations. SSCP for
exons  4–11  of  the  gene  on  tumor  DNA  from  the  two  sisters
revealed an abnormal conformer in exon 6. DNA sequence analy-
sis showed a transversion from adenine to cytosine at codon 220
(amino acid change from tyrosine to serine). The same pattern was
observed on microdissected paraffin-embedded tissue of both the
mother and the brother. We generated, by site-directed mutagen-
esis, a plasmid encoding the p53SER220 mutation (pLp53-S220).
We transfected fibroblasts from p53 –/– mice (F10) with pLp-S220
and pLp53-H175 (a plasmid encoding the p53His175 mutant). The
presence of the two mutations did not increase the proliferation
rate of F10 fibroblast. Drug sensitivity (assessed by IC50 value) of
the fibroblasts carrying the mutations was evaluated for doxoru-
bicin,  cisplatin  and  5-florouracil.  Fibroblasts  carrying  the
p53SER220 and p53His175 mutations showed a selective resistance
for doxorubicin with, respectively, a 3.5- and a 2.9-fold increase.
These data were confirmed by the evaluation of the clonogenic
ability of the fibroblasts carrying the different transfectants. In con-
clusion, the p53SER220 germ-line mutation seems to induce a gain
of function in term of chemoresistency for the mutated p53 pro-
tein.
Prognostic  role  of  metalloproteinases  in  soft  tissue
sarcomas
M.S. Benassi, G. Gamberi, G. Magangoli, M. Merli, L. Molendini,
P. Ragazzini, F. Chiesa & P. Picci
(Laboratorio  di  Ricerca  Oncologica,  Istituti  Ortopedici  Rizzoli,
Bologna, Italy)
Aim: The earliest stage of the process of tumor invasion is an
increased permeability to malignant cell movement resulting from
an extracellular matrix (E_CM) degradation by proteases. High
levels of metalloproteases (MMPs) have been related to cell meta-
static potential and, inversely, the presence of specific MMP inhib-
itors  (TIMPs)  could  suppress  metastasis  preserving  ECM
integrity. The aim of this study was to evaluate the prognostic role
of MMP2, MMP9 and TIMP2 expression in relation to disease-
free survival (DFS) in 73 patients (32 relapsed and 41 disease free)
with soft tissue sarcomas.
Materials: The tumors included 29 liposarcomas (11 low grade
and 18 high grade), 15 malignant peripheral nerve sheath tumors
(MPNST), of which four low grade and 11 high grade, and 29 syn-
ovial sarcomas (14 spindle cell monophasic and 15 biphasic). The114 Abstracts
expression and distribution pattern of enzymes was evaluated by
immunohistochemistry on paraffin-embedded tissue, while their
level was calculated by immunoblotting analysis on fresh tissue.
Results: MMP2 reactivity showed a significant correlation with
the metastatic event (p<0.001) and grading (p<0.001), while the
lack  of  TIMP2  expression  was  a  variable  for  poor  prognosis
(p<0.01).  The  difference  between  the  DFS  curves  based  on
MMP2 and TIMP2 expression was statistically significant (p<0.01
and p<0.05, respectively).
Conclusions: An  unbalance  in  the  protease/protease  inhibitor
system as seen from our data may increase soft tissue tumor aggres-
siveness.  Finding  new  easily  evaluable  prognostic  factors  could
improve treatment and subsequently prognosis for these patients.
Outcome  after  limb  salvage  and  reconstruction  with
massive allograft after resection of sarcoma. Results more
than 5 years after surgery
N.J.  Lindner,  R.W.  Rödl,  Ch.  Hoffmann,  G.  Gosheger,  F.
Böttner, T. Ozaki, C. Gebert & W. Winkelmann
(Orthopaedic Department, University of Muenster, Albert-Schweitzer-
Str. 33, 48149 Münster, Germany)
Purpose: Results of reconstructive surgery after five or more years
using massive allograft transplantation.
Material and methods: One-hundred and fifteen reconstructions
with massive  allografts  were performed in patients with  various
tumors who underwent limb salvage at a single institution more
than five years ago. Among them 33 patients had Ewing’s sarcoma,
45 had osteosarcoma, 15 had chondrosarcoma, and two each had
malignant fibrous histiocytoma of bone, leiomyosarcoma of bone,
synovial sarcoma and 13 had other benign and malignant lesions.
All grafts were procured according to the guidelines of the Euro-
pean association of tissue banks and received gamma sterilisation
with cobalt-60 25 kGy.
Results: Twelve patients had large defects in the humerus, 42 in
the femur, 33 in the tibia, 19 in the pelvic region, and nine in other
regions. Osteosynthesis consisted of intramedullary rods, AO plate
or screw and K  wire fixation. Intercalary, arthrodesis  and joint
reconstrucion was performed. All grafts were longer than 10 cm.
Twenty-three grafts were removed due to infection and fracture
and revision with another limb salvage procedure was performed.
Two patients with pelvic allografts had to be amputated due to
infection and local recurrence. Skin problems, type of resection,
intrapoperative blood loss, cementation of allografts did not signif-
icantly influence the  infection rate. The difference between the
average tumor volume with and without an early infection was sig-
nificant. The average volume of allograft with an infection was sig-
nificantly  larger  than  that  without  infection.  The  difference
between duration of surgery in patients with and without an early
infection was significant.
Conclusion: Reconstruction  of  large  bone  defects  after  tumor
resection has a high complication rate. Osteosynthesis has to pro-
vide a sturdy fixation to protect the graft and allow healing of the
junctions to host bone. Once fusion occurs the complication rates
are minimal.
The  combination  vascularised  fibula/massive  bone
allograft. Imaging analysis at an over 5-year follow-up
M. Manfrini, D. Vanel, M. Innocenti1, C. Malaguti, M. De Paolis,
M. Ceruso1 & M. Mercuri
(Istituto Ortopedico Rizzoli, Bologna and 1CTO, Firenze, Italy)
In a homogeneous group of 32 lower limb skeletal reconstructions
performed from February 1989 to May 1995, a vascularised fibula
autograft (VFA) was inserted into a massive bone allograft (MBA),
cut as a trough. Implant biological behaviour was investigated on
the basis of serial radiological examinations obtained in 22 patients
regularly  followed  for  an  average  time  of  91  months  (range
60–132). Mean age was 13 years (range 4–30)  and 17 patients
received neoadjuvant chemotherapy.
Methods: All  patients  were  studied  by  standard X-ray every  6
months in the first 5 years and then every year; in all cases an aver-
age of three CT postoperative evaluations (two to six) at—over 1-
year—intervals were performed with the same CT Unit. Computer
assisted analysis was performed at three constant levels within the
reconstruction, so that the subsequent CT exams could be com-
pared. The following measurements were recorded :VFA Maximal
Sagittal  and  Transverse  Diameter,  Total  and  Medullary  Area,
Maximum Cortical Thickness and Cortical Density; MBA Corti-
cal Thickness and Cortical Density. Parametrical statistical com-
parison  of  the  first,  second  and  third  postoperative  year  was
performed by t-tests.
Results: Radiographic  analysis  reveals  two  patterns,  variably
mixed in each case: (A) when MBA cracks, load over VFA rapidly
increases. Living fibula produces a fast, dense cortical hypertro-
phy.  (B)  MBA  preserves  its  original  strength  and  absorbs  the
majority of load. Living  VFA presents  a progressive  but slower
enlargement of both external and medullary diameter with a low-
density cortex. Serial CT analysis demonstrated statistically signif-
icant  changes  in  both  VFA  diameters  (p<0.001)  and  areas
(p=0.0001). These increments increased between the second and
third  p.o.  year  when  all  patients  abandoned braces.  From  the
second p.o. year, a layer of ossification appeared on the endosteal
surface  of  the  allograft;  tissue  between  VFA  and  inner  MBA
showed  a  slow  maturation  with  axial  bridges  between  the  two
bones. After 5 years the inner fibula completely fused to the allo-
graft that, if mechanically intact, appeared almost completely sub-
stituted  by  new  reactive  bone.  VFA  can  rapidly  adapt  to  new
mechanical situations: cortical changes are directly correlated to
load. Serial radiological analysis shows complete remodelling of
MBA with inlaid VFA and suggests bone-inductive activity of VFA
on the endostal surface of MBA.
Results after five or more years of 95 allografts used in the
treatment of mbt of children and adolescents
M. San-Julian & J Cañadell
(Dpto.  Traumatología,  Clínica  Universitaria,  Avda.  Pio  XII  36,
31008 Pamplona, Spain)
Aim: To evaluate the  long-term  follow-up  results  of allografts
used in limb reconstructions of children and adolescents.
Methods: 95 massive allografts used in 80 patients younger than
20 years were followed during 5 or more years (June 1987–January
1995). The mean age was 14 (4–19) years. The mean follow up
was nine years (5-13).  Forty-two were intercalary allografts, 19
were osteoarticular and 34  were composite  allograft–prosthesis.
The histological diagnoses were osteosarcoma (66 cases) Ewing’s
(11  cases),  fibrosarcoma  (three  cases).  All  patients  received
chemo- and/or radiotherapy according to our protocols.
Results: 14 patients required two allografts due to complications
or bone metastases of their primary sarcoma. Seven patients suf-
fered infection, three suffered fractures and two required exchange
of the allograft due to non-union. Functional results were better in
intercalary allografts (88% of excellent and good results, including
those  who  were  treated  for  any complication).  The number  of
patients with any complication was lower than the number of allo-
grafts having complications (some patients had two or more com-
plications).  Limb  length  discrepancies,  when  present,  were
successfully corrected by bone lengthening or taking benefit from
any complication requiring allograft exchange.
Conclusion: Allografts in children and adolescent have a higher
complication rate than those used in adults. However, this numberAbstracts 115
of complications can be reduced very much by coverture of the
allograft, using intramedullary nailing, advising the possibilities of
late infection, etc.
Tumours of the pelvis and hip joint: methods and outcome
of surgical treatment
J. Somville, S. Maiya, A. Taminiau & R. Grimer
(Orthopaedic  Oncology  Service,  Royal  Orthopaedic  Hospital,
Birmingham, UK)
Purpose: To assess outcome and function following surgery for
non-metastatic primary bone tumours of the pelvis and the hip in
order  to  try  and  ascertain  the  ‘best’  procedures  for  different
tumour sites.
Method: 300 patients with non-metastatic primary bone sarco-
mas of the pelvis and proximal femur from three treatment centres
in United Kingdom, Belgium  and The Netherlands, have been
reviewed to investigate  the  outcome both in terms  of function,
complications and survival. Standard assessment tools (MSTS and
TESS scores) have been used.
Results: The tumours tended to present in similar  ways—non-
specific pelvic pain and referred pain—with long delays in diagno-
sis being common (mean 56 weeks). Tumour size averaged 13 cm
at diagnosis and was little different for the three main tumours.
There were 57 osteosarcomas, 49 Ewings, 185 chondrosarcomas
and nine others. Tumour locations included 55% in the pelvis and
45% in the proximal femur. The distribution of the pelvic tumours
were almost equal in the three sites (P Class) with a slight predom-
inance in the acetabular area. Treatment for all tumours was sur-
gical with appropriate adjuvant chemotherapy and or radiotherapy
as indicated. The overall survival of the patients was 64% at 5 years
and was related to tumour type and grade; 89% patients had limb
salvage surgery and 11% had amputations. The survival rates fol-
lowing amputation were worse than after limb salvage. Prognostic
factors  for  survival  were  assessed  and  will  be  discussed.  Local
recurrence arose in 24% patients and was related to: diagnosis,
size,  localization and surgical  margins. Complications  following
surgery were related to type of surgery and margins. There were
more  complications  following  limb  salvage  surgery,  with  6%
patients subsequently requiring amputation because of failure of
their limb salvage either related to local recurrence (23% cases) or
major  complications.  Functional  outcomes  were  worse  in  all
patients with pelvic tumours than proximal femoral tumours but
patients with uncomplicated Limb salvage did best.
Conclusion: Pelvic and hip tumours present the greatest challenge
to  orthopaedic  oncologists.  Successful  Limb  salvage  surgery  is
always better than ablative surgery, but marginal surgery for sarco-
mas and inadequate reconstruction lead to both oncological and
reconstructive complications which may mean that the patient is
worse off than with a primary amputation. Careful assessment of
all the risks must be taken into account when planning these pro-
cedures.
Uncemented fixation of massive implants. the first 9 years
J. Cobb, F. Muir, G. Blunn, J. Witt, T. Briggs & S. Cannon
(The London Bone and Soft Tissue Tumour Service, The Middlesex
Hospital and University College London Hospitals NHS Trust)
Massive replacement for malignant disease has been our standard
form of reconstruction. In the paediatric and adolescent skeleton,
cemented fixation was successful in the short term, but inevitably
failed in the medium and longer term. We developed uncemented
fixation using hydroxyapatite coating in 1991.
Method: Patients  with an osteosarcoma or other sarcoma were
offered uncemented fixation as an alternative to cemented fixation
if the resection plane had a reasonable length of diaphyseal bone
remaining.  One  hundred  and  forty-six  patients  had  massive
replacements  between  1991  and 1999.  All  had hydroxyapatite-
coated stems and collars. They have been followed by serial radio-
graphs and clinical signs.
Results: Eight prostheses(6%) have required revision for loosen-
ing. In all of these, primary fixation failed. All have been revised
without incident. Eight have become infected (6%). three of these
had documented Hickman line infections. Seven have been suc-
cessfully revised with two stage procedures, while one was ampu-
tated. There were also seven amputations for local recurrence, and
five other unplanned operations. Radiographs viewed serially show
no progression of radiolucency in the well fixed prostheses, and a
steady increase in the volume of bone at the shoulder of the pros-
thesis while the pedicle matures into the collar. Following this, the
bone mass diminishes slightly, but in otherwise healthy patients,
the bone mass and the bone-implant interface stabilise and do not
deteriorate.
Discussion: Fixation with hydroxyapatite-coated stems in diaphy-
seal bone is reliable and shows no sign of deteriorating with age.
Comparison with cemented implants shows that the uncemented
interface is more reliable and durable. The interface matures with
time and may represent real osseomechanical integration.
Van Nes rotation plasty for malignant bone tumors of the
distal femur
A.H.M. Taminiau
(Leiden  University  Medical  Centre,  Oncologic  Orthopaedics,  The
Netherlands)
Introduction: Limb salvage surgery for primary malignant bone
tumors has become worldwide accepted. The development of new
imaging techniques (MRI), neoadjuvant chemotherapy protocols
and  surgical  reconstructive  procedures  (tumor-endoprosthesis,
allografts) have made limb salvage feasible in the majority of the
cases. However due to age, site, size and tumor extension, ablative
surgery is inevitable in a certain amount of the patients. Curative
treatment in combination with preservation of a substantial part of
the leg and foot for tumors around the knee has recently been real-
ised by the introduction of rotation plasty (van Nes) of the lower
leg  as  an alternative  for  above knee  amputation  in  those  cases
where other types of reconstruction are not feasible. In rotation
plasty the tibia is rotated 180° degrees and fixed to the proximal
femur. The ankle joint is planned at the same level as the opposite
knee and can act functionally as a knee joint. The appearance of
the rotated foot at the level of the knee compensated wearing the
prosthesis still remains to be a cosmetic disadvantage. With this
innovative and advanced surgical technique a wide resection of a
malignant  tumor  is  performed.  A  major  advantage  of  rotation
plasty is that postoperative rehabilitation of these patients can be
established relatively early after the operation and, more impor-
tantly,  that  rehabilitation  is  superior  to  that  after  amputation
through the upper thigh.
Material and methods: Our indications for rotation plasty are sar-
coma of the distal femur (Enneking’s Stage IIB), no involvement
of the sciatic nerve, normal ankle function and acceptation of the
procedure by the patients and their relatives. In 273 limb salvage
procedures of primary malignant bone tumors  of the  femur 41
rotation plasties were performed in Leiden since 1982. The pre-
dominant diagnosis was osteosarcoma 33, Ewing five, MFH three
and chondrosarcoma one. There were 22  men and 20  women.
Medium age was 5 (two), 10 (four), 13 (six), 18 (16), 24 (three),
28 (three), 31 (one), 37 (five), 42 (one). We had stage IIB in 33
and stage IIIB in nine. The main contraindication is tumor invol-
vement of the sciatic nerve. There were no recurrences. Twenty-
four patients died of their disease due to metastases: <1 year, nine;116 Abstracts
1–2 years, eight; 2–3 years, six; and after 4 years, one. Eighteen are
alive without evidence of disease, including two after metastasec-
tomy >5 years after thoracotomy. Detailed quality of life in the sur-
viving group of patients was studied. The results show that physical
functioning  was  poorer  than  healthy  persons  but  psychological
functioning was highly comparable. To get better insight in the fea-
sibility of this procedure several items concerning technique and
outcome were studied. This study encloses vascular resection and
reconstruction instead of preservation, explanation for the absence
of oedema, analysis of the muscle function after rotation and the
functional results.
Discussion: Rotation  plasty  of  the  lower  leg  is  a  functionally
attractive  alternative  to  conventional  amputation  through  the
upper thigh for malignant tumors of the distal part of the femur.
Rotation plasty in many instances provides wider surgical margins
than  traditional  limb  salving  resections  while  providing  better
function then traditional amputation. However, the prognosis is
poor in this group mainly due to the large tumours requiring this
alternative for amputation.
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Function after ‘hindquarter amputation’
J. Metcalfe, R.J. Grimer & C Eiser
(The  Royal  Orthopaedic  Hospital  Oncology  Service,  Bristol  Road
South, Birmingham, UK)
Purpose: Hindquarter amputation was once described by Gordon
Gordon-Taylor as ‘… a rather vulgar term but one which expresses
the  extent  of  the  human  immolation’.  Despite  several  papers
describing  the  outcome  of  hindquarter  amputation  in  terms  of
patient survival and complications, there has been no structured
review of survivors to assess their quality of life and functional out-
come.
Material and method: We have performed 103 hindquarter ampu-
tations in the past 28 years, mostly for chondrosarcomas of the
pelvis but also for osteosarcoma, radiation-induced sarcoma and
soft tissue sarcomas. Twenty-one of the patients remain alive and
disease free and agreed to participate in answering a questionnaire
which had been accepted by the local Ethical Committee. We used
well accepted tools to measure quality of life (SF 36), function
(MSTS and TESS scores), sexual functioning (IIEF) and we also
asked specific questions about the use of artificial limbs and the
problems encountered.
Results: The SF36  scores confirmed the  generally  low level  of
achievement of all patients, well below the norm but interestingly,
when compared with other patients with long standing illness they
had comparable scores for social functioning, mental health and
general health perception. Wound healing took an average of 5.7
months. All had been offered an artificial limb but only four regu-
larly wore it for most of the day. Nine never used the artificial limb.
The main complaints were that it was heavy and cumbersome and
had to be taken off completely for defecating (all patients) and for
passing  urine  (females).  Phantom  pain  was  very  common,  still
being experienced in all  but one patient, treatment  was on the
whole unsuccessful. The TESS scores revealed many difficulties in
daily life, especially gardening, kneeling, walking up hills and self
rating. The IESS score confirmed that impotence was the norm
following these operations, causing considerable distress to those
concerned.
Conclusion: Hindquarter amputation is usually only considered as
a  last  resort  in  terms  of  controlling  cancer.  The  information
obtained from this study documents the true price patients pay for
undergoing this operation.
Non-surgical local treatment for high-grade non-metastatic
osteosarcoma (OS) of the extremities
G. Matchak, P. Sinyukov, S. Tkachev, V. Tepliakov, B. Bokhian
& A. Ryjkov
(N.N. Blokhin Cancer Research Centre, Kashirskoye sh.24, 115478
Moscow, Russia)
Purpose: To evaluate the oncological outcome of patients, that
were treated with neoadjuvant chemotherapy and who refused sur-
gery for primary tumour.
Patients and methods: Between January 1, 1988, and December
31, 1999, 23 OS patients received primary chemotherapy (PCH),
local radiotherapy 55–60 Gy ± adjuvant chemotherapy. The ages
ranged from 14 to 30 years with a mean of 18. There were 11M/
12F. The most common sites were proximal tibia (16) and distal
femur (five). PCH consisted of three to five cycles of intra-arterial
CDP 150 mg/m2 (17 patients) or DOX 90 mg/m2 (six patients).
During induction, the imaging response was assessed by analysis of
tumour size, sclerotic changes of extraosseous mass (X-ray, CT,
MRI),  tumour  neovascularisation  and  perfusion  (angiography,
three-phase bone scintigraphy), 99mTc uptake (plain scintigraphy)
and alkaline phosphatase levels. When all factors were evaluated as
effective the final evaluation of the imaging response was effective.
Limb function was estimated according to the Enneking classifica-
tion.
Results: Long-term follow-up (median 39) has shown an over-
all 5-year survival of 52% (95% CI 25–78%). Fourteen patients
are  continuously  progression-free  6–94  months  (median  36).
Limb function after PCH and during follow-up was excellent in
19 patients (83%). Nine patients relapsed, four with metastatic
disease, one with  local  progression  (LP)  and four with  both.
Local progression occurred in five (22%) cases, from 5 to 48
months (median 15) after the completion of radiotherapy. Eight
patients  (35%)  developed  metastases  from  5  to  65  months
(median 10). Prognosis was closely related to the chemotherapy-
induced imaging  response.  Retrospectively,  10  of  23  patients
(43%) were classified  as imaging responders (IR), 13 as non-
responders (NR). No LP were observed in IR compared with
five  LP  in  NR  (p<0.02).  Two  of  five  patients  with  LP  were
treated by amputation and one by bone resection with endopros-
thetic replacement. The 5-year actuarial metastases-free survival
rate  was  100%  (95%  CI  100–100%)  and  36%  (95%  CI
11–73%), respectively, for IR and NR (p<0.001). Two patholog-
ical fractures and three postradiation fibrosis were noted after
radiotherapy.
Conclusions:  In  patients  with  pronounced  imaging  response  to
PCH, the substitution of surgery by radiotherapy in a dose 55–60
Gy had no adverse effect on the local and systemic disease control.
Perhaps, a new approaches for local OS treatment will be discussed
in the near future.Abstracts 117
Minimally  invasive  radiofrequency  therapy  for  the
treatment of local tumour recurrence
M.A. Hall-Craggs, J.D. Witt, J.P. Cobb, S. Bown, J. Whelan & A.
Cassoni
Introduction: Surgical resection with wide margins offers the best
chance of achieving a cure and preventing local disease recurrence
in patients with low grade malignant and aggressive benign musc-
uloskeletal  tumours.  If  disease  recurs  treatment  options  are
restricted as surgery may be limited by the tumour site and extent,
and these tumours are relatively chemo- and radio-insensitive. An
alternative approach to controlling local disease is to use locally
applied minimally invasive therapy and a number of different tech-
niques are currently being investigated. These aim to cause maxi-
mum local tumour destruction with minimal collateral damage. In
this pilot study we report our initial experience of using radiofre-
quency thermal ablation in five patients with local tumour recur-
rence where disease was not amenable to conventional therapy.
Methods: Three  women  and  two  men  with  locally  recurrent
tumours (three chondrosarcomas, one chordoma and one MFH)
were treated with percutaneously applied radiofrequency probes.
The RF systems (Radionics, Europe) were of a cooled tip design
and single probes or clusters were used. Probes were positioned
using CT, MR or ultrasound guidance and all treatment was per-
formed as an inpatient procedure under general anaesthesia.
Results: Two patients had single treatments and the remainder
had two or more treatments. Therapy in the two patients with large
volume disease was not clinically effective in the short to medium
term, although there was treatment effect, this was insufficient to
control the growing disease. Two patients with small volume dis-
ease (<20 ml) currently have good local disease control at 18 and
11 months follow-up. The remaining patient opted for further sur-
gery shortly after the RF therapy. Complications of the technique
include skin necrosis  (one), local discharge (two), bowel fistula
(one) and transient nerve damage (two).
Conclusions: These preliminary results suggest that local disease
control may be gained in patients with small volume tumour recur-
rence but that previous surgery and radiotherapy may increase the
likelihood of treatment complications.
Stump  lengthening  after  hip  disarticulation  by  using  a
MutarsÒ  endoprosthesis
G.  Gosheger,  A.  Hillmann,  N.  Lindner,  T.  Ozaki  &  W.
Winkelmann
(Department of Orthopaedics, University Hospital, Albert-Schweitzer-
Str. 33, 48149 Muenster, Germany)
Introduction: A severe functional and cosmetic loss develops after
hip disarticulation to obtain wide surgical margins. In contrast to
hip disarticulation, above-knee amputation is much more common
after trauma or ischemia, and people are familiar with the func-
tional and cosmetic aspect.
Methods: We developed a special surgical procedure in patients
with  tumors  of  the  proximal  femur  involving  the  sciatic  nerve.
After hip disarticulation a flap is preserved. A modular endopros-
thesis is placed into the acetabulum. A trevira tube is applied to the
reconstruction of the joint capsule and fixation of soft tissues. We
perfomed  this  procedure  in  five  patients.  One  patient  had  an
infected endoprosthesis, one a malignant fibrous histiocytoma, one
a fibrosarcoma, one a leiomyosarcoma, and one a hemangioen-
dothelioma. The follow-up ranged from 3 months to 20 months
(3, 6, 19, 19, 20 months).
Results: The primary wound healing did not present any prob-
lems. We could reach stump lengths of 23, 27, 31, 25 and 41 cm.
All patients could wear an above-knee prosthesis. According to the
MSTS-score (Enneking), the functional results were good. We did
not observe severe blisters or horny skin after wearing the prosthe-
sis especially in load bearing zone. All patients could walk without
crutches for short distances. For ambulation of middle and longer
distances the patients used one crutch or a cane. The radiographic
follow-up showed good articular conditions and no local recur-
rence. One patient died because of pulmonary metastasis.
Conclusion: Stump  lengthening  by  using  a  modular  prosthetic
system is a convincing alternative to hip disarticulation. The short-
term results show good functional results. The middle- and the
long-term results have to be evaluated. Even for the upper extrem-
ity this possibility of reconstruction can be available.
Evaluation  of  chemotherapy  response  in  primary  bone
tumors  with  F-18-FDG-PET  in  comparison  to  TC-99m-
MDP bone scintigraphy
F. Böttner, C. Franzius, N. Lindner, J. Sciuk, C. Brinkschmidt, H.
Jürgens & W. Winkelmann
(Departments of Orthopaedic Surgery, Nuclear Medicine, Pathology
and Pediatric Oncology, University of Muenster, Germany)
Purpose: Usually, bone scintigraphy is used for the assessment of
neoadjuvant  chemotherapy  response  of  osteosarcomas  and
Ewing’s sarcomas. We evaluated the potential of F-18-FDG-PET
to assess chemotherapy response.
Patients and Methods: 15 patients with primary osseous tumors
(10 osteosarcomas, five Ewing’s sarcomas, age range 5–36 years,
median 13 years) were studied with F-18-FDG-PET and planar
Tc-99m-MDP bone scintigraphy before neoadjuvant chemother-
apy and preoperative. Tumor response was classified histologically
by analysis of the resected specimen according to Salzer-Kuntschik
(grade I–III, good response with <10% vital tumor areas; grade
IV–VI, poor response with Š10% vital tumor areas). PET was per-
formed in whole-body technique (scanner ECAT EXACT 47, Sie-
mens), bone scintigraphy in usual three-phase technique. In both
imaging  modalities,  quantification  was  done  using  tumor/non-
tumor  ratios  (T/NT).  The  percental  reduction  in  T/NT  ratio
between baseline and follow-up examination was determined.
Results: 13  patients  were  classified  as  good  responders  (six
patients II, seven III), two patients were classified as poor respond-
ers (IV and V). FDG-PET showed a more than 30% decrease in
T/NT ratios in all good responders, whereas three of these patients
had  increasing  bone  scan  T/NT  ratios,  and  another  four  had
decreasing ratios of less than 30%. In one of the two poor respond-
ers FDG-PET T/NT ratio was enhanced, and bone scan T/NT
ratio showed a low reduction of 19%. The other poor responder
had a decreasing FDG-PET T/NT ratio of 11%, and an increasing
bone scan T/NT ratio.
Conclusion: The low correlation between PET and bone scanning
indicates that different aspects of the tumor metabolism are meas-
ured.  In  this  small  patient  group,  F-18-FDG-PET  accurately
assesses the effect of chemotherapy on primary osseous tumors.
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Neoadjuvant  chemotherapy  cisplatin  (DDP)+adriamicin
(ADR) combined with regional hyperthermia (RHT) in the
treatment of primary high-risk soft tissue sarcomas
B.  Bokhyan,  S.  Ivanov,  R.  Karapetyan,  A.  Gevorkian.,  V.
Tepliakov & S. Tkachov
(N.N. Blokhin Russian Cancer Research Centre., Kashirskoe sh. 24,
Moscow 115478, Russian Federation)
Aim: The  efficacy  of  neoadjuvant  thermochemotherapy  was
investigated.
Patients and methods. We report the results of phase I/II studies of
treatment of 22 patients with II and III grade extremities soft tissue118 Abstracts
sarcoma  (STS).  All  patients  had  extracompartmental  lesions,
tumour size > 8 cm (mean 12 cm). Mean tumour volume was 540
cm3. The preoperative chemotherapy with DDP 120 mg/m2 and
ADR 90 mg/m2 (1 day) for 6 weeks (two cycles) combined with
two fractions of RHT (60 min, 43.0°C) days 1, 3.
Results: Limb-saving surgery was performed in 19 (86.4%) cases
consisting of wide compartmental excision of the tumour. Mutilat-
ing surgery was performed in three cases. Treatment efficacy was
assessed by clinical, morphological response and follow-up for sys-
temic and local relapse. The efficacy rate was 50% or more. The
mean tumour necrosis (>70% cells) rate in the resected specimens
was  81.8%.  There  was  no  correlation  between  the  histological
response and the observed reduction in tumour volume. Postoper-
ative complications were observed in 10 (45.5%) patients; among
these, four patients developed wound infection that required sur-
gical treatment as a complication of surgery performed in the early
stage following the preoperative treatment. After a mean postoper-
ative follow-up of 27 months, distant metastasis  occurred in six
(27.3%) patients resulting in five fatalities. The 3-year cumulative
survival rate was 64.3%. No local recurrence was observed in any
patient during the follow-up, thus confirming our hypothesis that
DDP+ADR+RHT treatment has an excellent local efficacy.
Conclusions: The  results  of  this  study  suggested  that
DDP+ADR+RHT was an effective local treatment for limb sal-
vage in limb-threatening STS. We think that it would be valuable
to conduct, at many facilities, phase III studies on the treatment of
soft tissue sarcoma by a combination of surgery and preoperative
multidisciplinary treatment using hyperthermia.
Cytological diagnosis of high-grade osteosarcoma
O. Brosjö, A. Kreicbergs, H.C.F. Bauer, V. Söderlund, O. Larsson
& L. Skoog
(Orthopedic  Oncology  Service,  Karolinska  Hospital,  Stockholm,
Sweden)
Patients  and  methods: In  a  consecutive  series  of 47  high-grade
osteosarcoma (OS) cases 1992–99, fine needle aspiration biopsy
(FNAB) was performed in all.
Results: According to age, location, and radiological appearance,
31 of the 47 lesions were typical, classical, high-grade OS. FNAB
was  diagnostic  in  30  of  these  31  cases.  In  one  of  four  cases
undergoing  also  open  biopsy,  cytology  showed  sarcoma  NOS,
whereas histopathology classified the lesion as high-grade OS. As
for  the  remaining  16  cases,  eight  had  an  atypical  radiological
appearance. In these, cytology was diagnostic for high-grade OS in
three  cases.  The  remaining  five  were  cytologically  classified  as
sarcoma  NOS  (two),  low-grade  OS  (one),  GCT  (one),  and
inconclusive (one). In another subset of eight cases, both location
and radiology were  atypical.  Cytology  was  diagnostic  for  high-
grade OS in two cases. The other six were classified as sarcoma
NOS  (three),  Ewing’s  sarcoma  (one),  and  inconclusive  (two).
Because  of  inconclusive  cytology,  non-specific  sarcoma  or
incongruity  between  clinical  data,  cytological  diagnosis,  and/or
radiological appearance, open biopsy was done in 14 of these 16
cases.  Thus,  in two cases,  definitive  surgery  was  done without
previous open biopsy as FNAB with certainty classified the lesions
as low-grade OS and Ewing’s: (1) a low-grade OS according to
cytology (78 years old) was reclassified after wide excision as a
small cell OS; (2) a Ewing’s sarcoma in distal radius (14-year-old
boy)  with  clinical,  radiographical  and  immunohistochemical
findings complying with this diagnosis, was treated preoperatively
according to our Ewing’s sarcoma protocol followed by wide local
excision  (NED  after  5  years  follow-up).  However,
histopathological examination of the surgical specimen disclosed
an extremely uncommon small cell OS type, i.e., the epithelioid
variant, which is reported to exhibit not only a similar histological
picture as seen in Ewing’s/PNET, but also the same cytogenetic
translocation. Among the 16 atypical cases, histological assessment
was  associated  with  diagnostic  difficulties  in  seven,  requiring
second opinion by international expertise.
Conclusions: Our study shows that FNAB is reliable as a confirm-
atory diagnostic tool in typical, classical, high-grade OS. Thus, in
two-thirds of the cases open biopsy can be obviated. However, in
atypical cases, which are easily recognised, open biopsy should be
employed.
Results of the limb-preserving reconstructions in malignant
or metastatic tumours
A.N. Makhson & A.S. Burlakov
(Moscow Oncological Hospital #62, Moscow, Russia)
At the present time 324 patients who were operated for malignant
tumours of extremities by means of different reconstructive meth-
ods have been observed in our hospital during 5–28 years. Revas-
cularized fibular bone graft, different free soft  tissues  flaps  and
endoprotheses were used in extremity restorations. Microsurgical
procedures  were  performed  successfully  in  88  reconstructions.
None of the other surgical techniques allows to replace extensive
soft tissues defects. The free fibular bone grafting (32) is a method
of choice in cases of diaphyseal lesions. We did not have any seri-
ous complications  except  bone graft fracture (four) which hap-
pened in 1–2 years after the operation. The use of endoprotheses
is the most widespread and routine procedure. We used it in 236
cases: 149 proximal part of femur, 76 distal part and 11 total femur
prostheses.  The  most  serious  complications  that  we  had  were
among  the  distal  part  femur  reconstructions  and  appeared  in
15–28 years after operation (seven). In six cases we have to remove
the  endoprosthesis  and  repeat  reconstruction  using  free  fibular
bone grafting. In one patient we used Van Ness procedure. It is a
really serious problem to get bone consolidation in such patients.
Metallosis and dislocation of endoprosthesis that happens during
this period becomes a very serious problem, and can lead to ampu-
tation of the saved extremity. Based on our experience in treatment
of such patients we can conclude that in cases of distal lesion of the
femur and good prognosis of survivability, bone graft microsurgical
transferring should be managed despite creating knee arthrodesis,
especially for young patients.
Periosteal osteosarcoma
C.  Zambakidis,  S.R.  Cannon,  T.W.R.  Briggs,  J.  Cobb,  A.
Saiffudin & J. Pringle
(Institute of Orthopaedics, RNOHT Stanmore; The Royal National
Orthopaedic Hospital, Stanmore; The London Bone and Soft Tissue
Sarcoma Service)
Periosteal osteosarcoma is a rare variant of osteosarcoma. 16 cases
presenting  between 1980  and 1996  have been reviewed. There
were 12 female patients and their age ranged between 9 and 72
years. The predominant site was the proximal tibia, followed by the
distal femur. Many patients had a fairly prolonged period of symp-
tomatology  up  to  36  months  prior  to  surgery.  Treatment  was
diverse varying from disarticulation to wide local excision with or
without  graft,  occasionally  prosthesis  was  used.  The  historical
patients  did  not  receive  chemotherapy,  13  subsequent  patients
have been treated with standard osteosarcoma chemotherapy but
often  under shortened  courses. The  overall survival  in patients
treated by modern therapy is 92%. Results of reconstruction based
on muscular tumour society scoring varies from 20 to 100% with
a mean of 70%. There is some evidence that patients treated by
modern chemotherapy and local resection do better than historical
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Total femoral endoprosthetic replacement
L.A. David, S.R. Cannon & T.W.R. Briggs
(Royal National Orthopaedic Hospital Trust, London Bone and Soft
Tissue Tumour Service)
Study aim: A review of 11 patients who underwent total femoral
excision  and reconstruction for malignant tumours with  assess-
ment  of  outcome  using  the  Musculoskeletal  Tumour  Society
(MTS) Rating Score.
Methods: Information  was  gathered  from  Database  records,
patients’ case notes and by clinical review. The prostheses were all
custom-made incorporating either a Stanmore Mk-5 knee mecha-
nism  or  a  SMILES  (Stanmore  Modular  Individualised  Lower
Extremity System) device with four of the prostheses being extend-
able for use in children.
Sample: All patients who underwent total femoral replacement
for malignant bone tumours at the RNOH between June 1978 and
August 1999 were included. Of the 11 patients, six were male and
five were female. The age at operation ranged from 5 to 65 years,
with a mean age of 26 years and 8 months. The tumour type was
osteosarcoma in seven cases, chondrosarcoma in two, Ewing’s sar-
coma  in  one  and  malignant  fibrous  histiocytoma  in  one.  The
patients  had  previously  undergone  a  mean  of  3.5  procedures
(range 1–24). The mean follow-up was 39 months (range 7–111
months).  Ten  patients  also  received  chemotherapy  and  three
received radiotherapy.
Results: 2 patients died of metastases within 1 year. Three more
died within 5 years. Seven patients developed metastatic disease.
Three  patients  developed recurrences, which  were  treated with
excision  and radiotherapy. Two patients  needed revision of the
whole prosthesis (one for infection and one for failure of the grow-
ing mechanism) and one patient needed revision of the acetabular
component due to dislocation. Of those who survived 1 year or
more the average range of motion was 90° at the hip and 80° at the
knee. Using the MTS rating the outcome of one patient was excel-
lent, five were good and three were fair.
Conclusion: Total  femoral  endoprosthetic  replacement  can  be
used effectively in patients after excision of malignant tumours in
order to preserve the limb, with good function achieved in some
cases. However, there are many risks involved and the outcome is
extremely varied.
Oncological  outcome  aftfr  intralesional  surgery  in
chondrosarcoma
T. Charatishvili, Yu. Soloviev, M. Aliev & N. Trapeznikov
(N.N. Blokhin Cancer Research Centre, Kashirskoye sh. 24, Moscow,
115478, Russian Federation)
Purpose: To evaluate the outcome of 94 patients who underwent
IL surgery for chondrosarcoma.
Methods: There were 61M/33F. The ages ranged from 16 to 70
years. with a median of 40. Fifty-four tumours were located in the
axial skeleton and 40 in the extremities. The histological grade dis-
tribution of the chondrosarcoma was: 23 Grade I, 48 Grade II, 13
Grade  III,  five  mesenchymal  and five  dedifferentiated.  Median
follow-up time was 99 months.
Results: The 10-year overall survival rate for the 94 patients who
underwent IL surgery was 37%, and 56% for the 227 patients who
underwent  adequate  surgery  (p=0.02).  The  incidence  of  local
recurrence was 79 cases (84%) after IL surgery compared with 53
(23%) after radical surgery (p<0.0001). The 10-year metastases-
free survival rate for the who underwent IL surgery was 33%, and
54%  for  patients  who  underwent  wide  or  marginal  surgery
(p<0.002). In patients with IL surgery, the overall survival rates for
the patients with tumours of histological Grade I, II and III+ mes-
enchymal+dedifferentiated  was  73,  33  and  12%,  respectively
(p<0.0001).  The  overall  survival  rates  for  patients  with  central
tumours and extremity tumours were 29 and 47%,  respectively
(p>0.05).
Conclusions: IL surgery for chondrosarcoma often leads to local
relapse that results in metastases  and death. The prognosis for
patients  after  IL  surgery  tends  to  differ  according  to  tumour
grade.
Joint sparing surgery for malignant disease
J. Cobb, J. Witt, G. Blunn & P. Unwin
(The London Bone and Soft Tissue Tumour Service, The Middlesex
Hospital and University College London Hospitals NHS Trust)
Massive replacement to reconstruct after resection of malignant
tumours  is  difficult  close  to joints. Often the  joint is  sacrificed
despite being normal because implant fixation close to the joint has
been impossible.
Method: Extracortical plates (ECP) have been used in 27 cases
for metaphyseal fixation where conventional intramedullary stem
(IMS) fixation would have been impossible.
Results: At a mean of 22 months, no loosening has been observed,
and normal  joint  function  has  been  retained.  Prominent screw
heads have caused some minor discomfort.
Discussion: ECP  fixation  appears a  safe  mechanical  alternative
either with a biological or massive reconstruction. The wide meta-
physeal bone surface accommodates rapidly to the fixation with no
obvious loss of joint function. We now consider that 10 mm of
subchondral bone either side of the knee is sufficient for joint sal-
vage surgery. Routine resection of normal joints for reconstruction
purposes for oncological clearance should be reduced by up to
40%.
Adamantinoma of the long bones—the first bilateral case
M. Dominkus1, I. Sulzbacher2, C. Oettl3, R. Kotz1
(1Department  of  Orthopedics,  2Institute  of  Clinical  Pathology,  and
3Department  of  Radiology,  Vienna  Medical  School,  Waehringer
Guertel 18–20, A-1090 Vienna, Austria)
Since 1973, six patients with adamantinoma of the long bones
were  treated  in  our  institution.  All  of  the  two  men  and  four
women with a mean age of 45.7 years (33.7–62.8) had their loca-
tion in the tibia. The most recent case showed skip metastases
and a simultaneous presentation on both tibias. The time of clin-
ical symptoms ranged from 2  to 34 years. Most patients com-
plained  of  pain  and  swelling  in  the  diaphysis  of  the  tibia  or
pathological  fracture.  Histological  diagnosis  after  incisional
biopsy revealed adamantinoma in all cases, with tubular or spin-
dle cell pattern and epithelial nests which ruled out the differen-
tial  diagnosis  of  osteofibrous  dysplasia.  The  one  patient  with
bilateral presentation was the only one with skip lesions. There
was a single skip lesion in the left tibia proximal to the tumour and
two skip lesions were found in the right tibia, one located proxi-
mal  and  one  distal  to  the  main  mass.  The  histology  of  these
lesions did not differentiate from the main tumour. The treat-
ment  consisted of marginal resection in two, curettage in one,
amputation one and wide resection with consecutive biological
reconstruction with vascularized fibula or fibula pro tibia in two
patients (three legs). Local recurrence occurred in four patients.
After a follow-up period of 4 months to 15 years, three patients
showed no evidence of disease, one patient died of disease, one is
alive with disease and one patient was lost to follow-up 1 month
postoperatively. The presented case of a bilateral adamantinoma
is the first case reported in the literature, so far. Skip lesions in
one bone may promote a multifocal presentation.120 Abstracts
Malignant lymphoma of the bone
H.R. Dürr, P.E. Müller, E. Hiller, A. Baur & H.J. Refior
(Department  of  Orthopedics  and  Orthopedic  Surgery,  Ludwig-
Maximilians-University  Munich,  Klinikum  Grosshadern,  81366
Munich, Germany)
Study aim: Malignant lymphoma of the bone is rare. In many cases,
its diagnosis is delayed because of unspecific clinical signs and equiv-
ocal radiographs. Therapy in general is multimodal, including sur-
gery and radio- and chemotherapy. Our objective was to demonstrate
the clinical and radiological aspects of the lesion to optimize diagnos-
tic approaches and to evaluate treatment and prognostic factors.
Methods: Thirty-six  cases  of malignant lymphoma of the  bone
that were surgically treated over a 15-year-period were retrospec-
tively  reviewed. Seventeen of the cases  showed a singular bone
non-Hodgkin’s  lymphoma (NHL) which classified  them  as pri-
mary lymphoma of the bone (PLB). In 13 cases, dissemination of
the disease with multiple bone or visceral involvement was appar-
ent. Six patients suffered from bone involvement due to Hodgkin’s
disease. Surgical treatment was indicated for diagnostic reasons or
complications  due  to  the  disease. Radiation  and chemotherapy
were part of the oncological treatment.
Results: The mean age was 57 years. The main symptom in malig-
nant bone lymphoma in 33 patients was pain, with an average dura-
tion  of  8  months.  In  the  secondary  cases,  bone  involvement
appeared on average 57 months after the initial diagnosis. Fifty-
eight percent of the lesions showed an osteolytic pattern. Soft-tissue
involvement was seen in 71% of the cases and was the primary diag-
nostic sign associated with this disease. The 5-year survival rate was
61%. Multiple versus solitary bone involvement was the most sig-
nificant factor in the prognosis. Extraskeletal involvement signifi-
cantly  decreased  survival.  No  correlation  was  found  between
gender, age, location or histological sub-types, and survival.
Conclusions: Bone  involvement  in  NHL  appears  late  in  the
extraskeletal disease. The clinical appearance is non-specific, and
the delay between the onset of symptoms and diagnosis is often
long. One of the major radiological signs is the existence of a soft-
tissue tumor surrounding the bone with little or no bone involve-
ment  on  plain  films.  Treatment  generally,  is  nonsurgical,  and
based on the stage of the disease. Local radiation with or without
systemic  chemotherapy  should  be  used.  Long-term  survival  is
favorable,  but  dependent  on  the  stage  of  the  disease  and  the
amount of bone involvement.
The MutarsÒ -trevira tube for reconstruction of capsule and
soft tissue in the endoprosthetic replacement of bone tumors
G.  Gosheger,  A.  Hillmann,  R.  Roedl,  Ch.  Hoffmann  &  W.
Winkelmann
(Department of Orthopaedics, University Hospital, Albert-Schweitzer-
Str. 33, 48149 Muenster, Germany)
Introduction: Large defects  after resection  of a malignant bone
tumor can be reconstructed by using a modular endoprosthesis. A
special problem consists of replacing the soft tissues and joint cap-
sules to the endoprosthetic device. There have been some reports
on dislocation of megaendoprostheses especially in the proximal
femur, total femur, and proximal humerus.
Methods: From 9/92 to 12/98 in the orthopedic department of the
University  of  Muenster,  69  Mutars-megaprostheses  were
implanted  using  a  trevira  tube.  The  endoprostheses  were
implanted  after  proximal  femur  resection  (n=33),  total  femur
resection (n=5) and proximal humerus resection (n=16). In these
cases the trevira tube is used for the reconstruction of the capsule
and for the refixation of muscles, and so far for avoiding disloca-
tion. In the case of proximal tibia replacement (n=7), arthrodesis
of the knee joint (n=3), total knee (n=2) and distal femur replace-
ment (n=3) the Mutars–trevira tube allows attaching muscle-flaps
and extensor tendon. The minimal follow-up was 9 months, the
maximal follow-up was 78 months, and the mean follow-up was
31.6 months.
Results: Regarding  the  unconstrained  megaendoprostheses
(proximal femur, total femur, proximal humerus) a dislcocation
was observed only in two of 52 patients (3.8%). These two cases
were proximal femur endoprostheses. No dislocation was observed
in  patients  with  a  total  femur  endoprosthesis  or  a  proximal
humerus endoprosthesis. Futhermore the trevira tube was used to
attach the gastrocnemius muscle in patients with a proximal tibia
endoprosthesis and to reattach the rotator cuff in patients with a
proximal humerus endoprosthesis. As  for the infection rate, we
could not observe significant increase of infection rates (p=0.46).
The histopathological findings of six revision cases showed a com-
plete tissue ingrowth into the tube.
Conclusion: By using the MutarsÒ -trevira tube for reconstruction of
capsule  and  soft  tissue  dislocation  of  megaprostheses  can  be
reduced. Furthermore the trevira tube can serve for the attachment
of flaps and muscles.
Results of reconstructive surgery for shoulder tumours
R. Gradinger; H. Rechl & R. Burgkart
(Clinic  of  Orthopaedic  Surgery,  Technical  University  Munich,
Ismaninger Str. 22, 81675 München, Germany)
From 1971 to 1987, 85 patients with primary (n=45) and second-
ary (n=47) malignant bone tumours of the shoulder region were
operated. The performed treatments were: only tumor resection
(n=30), refixation of the remaining humerus to the clavicula or
thoracic wall (n=4), cemented endoprotheses (Polyacetal, n=16;
Carbon Fiber, n=8; Modular Metal, n=3), space holder (n=2),
osteosynthesis  augmented  with  methyl  methacrylate  (n=  14),
fibula autografts (reconstruction of diaphysis (n=6) or proximal
humerus (n=4)), one arthrodesis and three fore-quarter amputa-
tions. All resections of the primary tumors were ‘wide’ and of the
metastases  ‘marginal’  or  ‘intralesional’.  The  average age  of  the
patients  with  endoprotheses  was  52  years  and  with  fibula
autografts 21.9  years.  The  mean  resection  length  was 12.7  cm
(endoprostheses)  vs.  19.6  cm  (fibula).  The  functional  results
according to the ISOLS criteria of the endoprotheses were good for
motion, strength, function and patient satisfaction and very good
for  pain,  deformity  and stability.  Complications  were  luxations
(n=2), local recurrences (n=2), loosening (n=1) and implant break
(n=2). The functional results of the fibula autografts as diaphyseal
spacer were good (n=3) or very good (n=3), but as reconstruction
of the proximal humerus fair (n=3) or poor (n=1). As complica-
tions  we observed  fractures (n=3),  which  could be successfully
treated by internal fixation.
Discussion: Most reconstructions of diaphyseal defects  demon-
strate excellent results, whereas salvage procedures of the proximal
humerus with resection of the rotatory cuff lead to poorer func-
tional results. An important difference between refixation of the
remaining humerus to the clavicula or thoracic wall and the recon-
struction of the proximal humerus with fibula or endoprothesis was
not obvious. For the treatment of primary bone tumors we prefer
biological solutions, whereas for palliative indications we mainly
use space holders or modular endoprostheses.
Chordoma of the sacrum and mobile spine. A study of 39
cases
P.  Bergh1,  B.  Gunterberg1,  L.-G.  Kindblom2  &  Jeanne  Mesi-
Kindblom2
(Departments  of  1Orthopaedic  Surgery  and  2Pathology,  The
Musculoskeletal Tumor Center, Sahlgren University Hospital, 413 45
Göteborg, Sweden)Abstracts 121
Study: A retrospective investigation of patients operated in Göte-
borg.
Aim: To identify prognostic factors. To demonstrate the impor-
tance of center-based treatment. To evaluate long-term outcome.
Materials and methods: Review and analysis of clinical and mor-
phological characteristics, type and place of diagnostic procedures
and surgery, and follow-up for 39 consecutive patients with chor-
doma.
Results: There were 30 sacral and nine spinal chordomas (3–20
cm, mean 8 cm) in 22 women and 17 men (mean age 55 years).
The pre-operative diagnosis was based on fine needle aspiration
(FNA) (16) or core needle or incisional biopsy (12) in those pri-
marily treated at our center. Definitive surgical margins were wide
in 23 and marginal or intralesional in 16. Mean follow-up was 8.1
years. Local recurrence occurred in 44%, metastasis in 28%. The
estimated 10- and 20-year survivals were 64 and 52%. Local recur-
rence  was  significantly  associated  with  metastasis  and  tumor-
related death.
Conclusions: Larger  tumor  size,  invasive  diagnostic  procedures
outside  our  center,  inadequate  surgical  margins,  microscopic
tumor necrosis, KI=67>5% and local recurrence are adverse prog-
nostic factors. FNA is the preferred method for histological diag-
nosis. En-bloc removal with adequate margins has improved local
control  and outcome,  which  did  not  differ  between  sacral  and
spinal tumor location.
Talocrural joint contact stress in rotation plasty
A. Hillmann1,  D.  Rosenbaum2, E. Eils2, L.  Renneberg1 & W.
Winkelmann1
(1Orthopaedic  Department,  Funktionsbereich  Bewegungsanalytik
(Movement  Analysis  Lab),  and  2University  of  Muenster,  Albert-
Schweitzer-Str. 33, 48149 Muenster, Germany)
Introduction: After  resection of a malignant bone tumor of the
femur rotationplasty is considered to be a treatment option beside
other  limb  salvage  procedures  like  endoprosthetic  replacement,
allograft  or  autograft  reconstruction.  The  shortened  limb  is
adapted to a prosthetic foot with a customized shaft and can be
fully loaded. However, due to the marked change in the loading
conditions of the foot degenerative changes in the ankle joint may
be promoted. The aim of the present study was to characterize the
changes in the loading conditions in the talocrural joint in order to
understand and—if  possible—prevent  the  development  of  joint
degeneration.
Materials  and  methods: Nine  fresh-frozen  leg  specimens  were
measured in two conditions: in a simulated single-leg stance and in
a simulated rotationplasty with the foot rotated and embedded in
a cast that was connected to a prosthetic foot. A loading frame with
a load cell above the specimens and a force platform underneath
was used to apply a load of 600 N (estimated body weight) and to
control  the  experimental  conditions.  The  load  was  gradually
increased to the  desired force level, kept constant for 10  s and
released. Fuji prescale film (type superlow) was cut according to
the shape of the talocrural joint surface, sealed against moisture
with surgical foil, and inserted in the joint between talus and tibia
from an anterior approach. The stained areas on the Fuji film were
scanned with a resolution of 300 dpi and analyzed with a freeware
program (OSIRIS) that determined peak and mean color intensity
(i.e., pressure), area and force. Furthermore, the distance of the
contact area to the edge of the talar facet was measured.
Discussion and conclusions: The present results demonstrate that
the foot that is loaded in an extreme equinus position after rota-
tionplasty is subjected to a marked change in talocrural joint con-
tact characteristics. Even though the externally applied load was
controlled the joint contact force decreased. This is most likely due
to the fact that the foot is embedded in a tightly fitted shaft that
leads to a dissipation  of a certain percentage of the  force. The
expected  posterior  translation  on  the  talar  dome  lead  to  a
decreased contact area. This was also associated with a higher con-
tact stress that might predispose the patients to an accelerated joint
degeneration.  The  options  for  modifications  of  the  prosthetic
design are limited but will be subject of further investigations.
This project was supported by a grant from the German Cancer Society
(Deutsche Krebshilfe e.V.). Grant No.: 70-2460-Hi I.
Chondrosarcoma of the pelvis, a 10-year review
D.G. Houlihan-Burne, T.W. Briggs & S. Cannon
(The Bone Tumour Unit, The Royal National Orthopaedic Hospital,
Brockley Hill, Stanmore, Middlesex, UK)
Study: A clinical, operative and histological review of 33 patients
with chondrosarcoma of the pelvis seen at our unit over a 10-year
period.
Aim: To examine the mortality rate and rate of recurrence with
respect to grade and anatomical site of tumour. Functional out-
come of patients depending on the type of surgical procedure per-
formed was also studied.
Methods: A retrospective analysis of cases.
Subjects: All patients seen at our unit over a 10-year period with
a primary diagnosis of chondrosarcoma of the pelvis.
Results: Of  the  patients  seen,  28  had  a  primary  tumour  diag-
nosed, the remaining five had recurrent tumours. The tumours
were  situated  in  the  acetabulum  (14),  the  pubic/ischial  rami
(seven), the iliac wing (six), the sacroiliac joint (four) and one in
the sciatic notch and in the gluteal soft tissues. Surgical procedures
included wide local excision (17), wide local excision and total hip
arthroplasty (two), hemipelvectomy and endoprosthetic replace-
ment (12), hemipelvectomy and fibula strut autologous bone graft
(one),  partial  sacrectomy  and  reconstruction  (one),  and  hind-
quarter amputation (one). The recurrence rate in the follow-up
period was 30% (10/33) and this was related to local tumour spill-
age at the time of surgery, histological grade, anatomical area of
tumour and type of operative procedure performed. Other compli-
cations of these procedures included dislocation and infection of
prosthesis requiring revision surgery.
Hyperthermic  isolated  limb  perfusion  with  TNF-A  and
melphalan  in  advanced  soft  tissue  sarcomas:
histopathological considerations.
l.Y.  Kollender,  M.  Gutman,  Lev-Chelouche,  S.  Abu-Abid,
Merimsky,  I.  Bickels,  A.  Nirkin,  G.  Flusser,  N.  Maruani,  B.
Lifschitz-Mercer, M. Inbar, J.M. Klausner & I. Melter
Background,  materials  and  methods: The  specimens  of  27  high
grade  extensive  soft  tissue  sarcomas  (STS)  and  three  desmoid
tumors of the extremities, after local treatment with hyperthermic
isolated limb perfusion (HILP) using TNF-a and melphalan, were
evaluated for the type and extent of tumor necrosis and other his-
tological local tissue changes. Limb preservation was the objective
in this selected group of advanced STSs, candidates for amputa-
tion or mutilating  surgery otherwise. The tumoral masses  were
obtained  6–8  weeks  after  HILP,  during  the  definitive  surgical
resection of the residual tumor according to protocol.
Results: Typical  histological  changes  were:  cystic  hemorrhagic
necrosis in the center of the remaining tumor with pericystic exten-
sive fibrosis. In eight cases more than 90% necrosis was achieved.
In  14  cases  the  percent  of  necrosis  was  between  60  and  90%
(including four cases of 80–90%). In eight cases less than 60%
necrosis was obtained. No correlation was found between these
histological responses and the anatomical location of the tumor,
whether the tumor was primary or recurrent, the type of previous
treatment  (systemic  chemotherapy,  radiotherapy)  and  its  size.122 Abstracts
Some correlation was found with the histological type of tumor
and with proximal or distal location in the limb.
Conclusions: This is the first serial histological description of the
effect of high dose TNF-a and melphalan administered via HILP
on the tumoral masses of limb STS. The small number of speci-
mens and especially the variability of tumors precludes definitive
conclusions from the observed correlations. Larger numbers and
more homogeneity of the histological types are needed in future
series.
CT guided core needle biopsy for muscoloskeletal tumors-
the diagnostic method of choice?
G. Flusser,  J. Issakov, N. Maruani, O. Merimsky, I. Meller, J.
Bickels, A. Nirkin & Y. Kollender
(Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel)
Bone and soft tissue lesions, primary and secondary, benign and
malignant were traditionally diagnosed mostly by open biopsies
done at the operating room under general anesthesia. This proce-
dure although very accurate from the diagnostic point of view has
disadvantages by means of morbidity, tumor contamination and
cost  effectiveness.  In  the  last  decade with  the  better  pathology
techniques and more experience core needle biopsies are taking
over in modern Orthopedic-Oncology centers.
Materials  and  methods: Between  January 1998  and  December
1999 114 CT guided core needle biopsies were performed in our
institution. The same radiologist performed all biopsies. The same
pathologist examined all the pathology material. There were 41
soft tissue lesions and 77 bony lesions. Age ranged from 20 to 85
years (mean 53 years). There were 51 females and 63 males.
Results: All biopsies were performed ambulatory with no imme-
diate complications. In three patients a post biopsy hematoma
was noticed, that resolved spontaneously. Of the bony lesions, 46
turned out to be malignant (nine high grade sarcomas, five lym-
phomas, seven multiple  myelomas  and 25  metastatic  tumors).
Eleven lesions turned out to be benign; in six cases the results
revealed normal bone. In two cases the diagnosis was osteomyeli-
tis. In 12 cases the biopsy result was inconclusive (15%) and open
biopsy was necessary for diagnosis. Of the soft tissue lesions, 19
turned out to be malignant (16 soft tissue sarcomas, two lympho-
mas  and  one  melanoma).  Twelve  lesions  were  diagnosed  as
benign tumors, three cases turned out to be normal tissue. Three
cases (7%) were inconclusive and were followed by open biopsy.
Two cases of soft tissue that were diagnosed as benign lesions on
core needle biopsy turned out to be malignant at definitive sur-
gery.
Conclusions: CT guided core needle biopsy for musculoskeletal
tumors seems to be accurate and reliable. Although some improve-
ment is required in our accuracy rate. We achieved overall accu-
racy rate of 87% (85% for bone lesions and 93% for soft tissue
lesions). The complication rate is negligible and the cost effect is
low. We recommend CT guided biopsy as the primary diagnostic
approach for muscoloskeletal tumors.
The cryo-hit system: a new device for cryosurgery of bones.
characteristics  and  technique,  illustrated  by series  of the
first 40 cases
I.Meller, J. Bickels, A. Nirkin & Y. Kollender
(The National Unit of Orthopedic Oncology. Sourasky Medical Center,
Tel-Aviv, Israel)
Introduction: Traditionally,  using  cryosurgery  for  bones  (the
pouring  of  liquid  nitrogen  in  an  open  system  according  to
Marcov’s  technique)  was  rare  because  it  is  a  cumbersome,
uncontrolled  and  dangerous  method  with  many  complications.
Israel’s Galil-Medical Ltd developed a sophisticated, modular, and
well  controlled system for cryotherapy of tumors  in soft  tissues
(liver, prostate). We describe  its modification for application in
bones  using  a  special  gel-medium  and a  specific  set  of  probes
developed for freezing bony walls.
Materials and methods: From 12/97 to 3/99, 40 patients (26 males
and  14  females;  age,  14–78  years)  were  treated  with  the  new
device.
Diagnosis: Giant cell  tumor (GCT), 15;  aneurysinal bone cyst
(ABC), seven; chondromyxoid fibroma (CMF), one; chondroblas-
toma, two; chondrosarcoma grade I, seven; metastatic bone dis-
ease (MBD), seven; osteosarcoma (OS), one.
Anatomical locations: Clavicle, one; proximal humerus, five; prox-
imal ulna, one; distal radius, two; pelvis (including sacrum), 11;
proximal  femur, three;  distal  femur,  eight;  proximal  tibia,  five;
distal tibia, two; foot (toe; calcaneus), two.
Results: The follow-up time is short (12–26 months). There was
one LR (in the sacrum) and two fractures (late; healed by conserv-
ative management). There was no wound infection, no skin lesions
and no neuro-vascular damages.
Conclusions: We present this new cryotherapy system in order to
show its unique technical advantages over the old traditional and
fearsome way of pouring liquid nitrogen into bony holes.
BeromunÒ   (TNF-A)  and  melphalan  for  limb  salvage  in
advanced  limb  neoplasms:  a  new  standard  of  care  for
irresectable soft tissue sarcomas
I. Meller1, M. Gutman2, D. Lev-Chelouche2, J.M. Klausner2, J.
Isakov, O. Merimsky, G. Flusser, N. Marouani, J. Bickels1 & Y.
Kollender1
(1The National Unit of Orthopedic Oncology, 2Department of Surgery
B, Sourasky Medical Center, Tel Aviv Israel)
Background: BeromunÒ   (recombinant  tumor  necrosis  fac-
tor—rTNF_) is a highly potential antineoplastic agent. However,
since  its  systemic  administration in humans resulted  in a life-
threatening septic shock-like syndrome, its use was abandoned
These systemic side effects were eliminated when Beromun® was
administered via isolated limb perfusion (ILP). Following its suc-
cess  in  treating  metastatic  melanoma  confined  to  the  limb
BeromunÒ  is now being used in order to prevent amputation or
mutilating  surgery  in patients  suffering from irresectable limb
soft tissue sarcoma (STS). Promising results have been achieved
in  260  patients  participating  in  four  clinical  trials  currently
underway worldwide. An overview of these results is presented,
with special  emphasis  on the  data from the Tel Aviv Medical
Center.
Methods: During  a 7-year period,  70  patients  with  high  grade
STS underwent 81 ILPs with high dose BeromunÒ  (3–4 mg) and
melphalan (1–1.5 mg/kg). There were 37 males and 33 females.
The mean age was 56 years (range 14–80 years). Histological sub-
types included malignant fibrous histiocytoma, synovial, liposar-
coma,  malignant  schwannoma, desmoid,  clear  cell,  epithelioid,
rhabdomyosarcoma, leiomyosarcoma, and unclassifiable. Thirty-
one patients presented with recurrent and 40 with very extensive
primary tumors. The tumors were located in the upper extremity
in 13 patients and in the lower extremity in 57 patients. All patients
were candidates for either amputation or extensive mutilating sur-
gery. ILP was performed via the corresponding vessels proximal to
the tumor. Resection of the residual tumor or tumor bed or limb
was performed 6–8 weeks after ILP, and all reported responses
were pathologically confirmed.
Results: Marked tumor softening occurred within 48 h, and in
tumors protruding through the skin, hemorrhagic necrosis was evi-
dent within 24 h. The overall response rate was 80%. Twenty-one
patients (30%) had a complete response and 40 (57%) had a PR.
In three  patients  (11%),  only minimal  regression  was observedAbstracts 123
(stabilization  of  disease).  Operative  mortality  was  3%  (two
patients).  Limb  sparing was  achieved  in  82%  (62/70  patients).
Amputation was performed in eight patients. Within a follow-up
period of 2–76 months (median 24 months), 30 patients (43%) are
dead, 31 (44%) are alive with no evidence of disease (median 49
months), and nine (13%) are alive with disease. Local occurrence
occurred in 16/60 evaluable patients (26%). Limb salvage and sur-
vival rates were not significantly different for gender, age, primary
vs. recurrent tumor, or tumor location. Mortality was significantly
higher for multifocal disease (73 vs. 29%) (p<0.05). Limb salvage
rates were also not different for the various histological subtypes.
There was  trend towards higher  response rates  in synovial and
clear cell sarcomas.
Conclusions: The  combination  of  BeromunÒ   and  melphalan
given via ILP appears to be effective in patients with advanced STS
confined to the limb, achieving a high response rate and limb pres-
ervation.
Deep soft-tissue sarcomas of the extremities. management
analysis of 120 consecutive patients
J. Bickels, Y. Kollender, O. Merimski, J, Isakov, G. Flusser, A.
Nirkin & I. Meller
(The  national  Unit  of  Orthopedic  Oncology,  Tel-Aviv  Sourasky
Medical Center, Tel-Aviv, Israel)
Deep  soft-tissue  sarcomas of the  extremities  often  present  as a
large mass near the major neurovascular bundle of the extremity.
The current study, based on the experience with 120 patients who
were  treated  for  deep  soft-tissue  sarcoma  of  the  extremities,
emphasizes the low local recurrence rate achieved by the judgmen-
tal use of neoadjuvant and adjuvant treatment modalities and opti-
mal surgical margins.
Materials  and  methods: Between 1992  and 1995,  120  patients
were diagnosed with deep soft-tissue sarcomas of the extremities.
There were 67 males and 53 females whose age ranged from 2 to
90 years (median, 56 years), and who presented with 96 tumors
of the lower extremity and 24 of the upper extremity. According
to the ISOLS (international Society of Limb-Sparing) guidelines,
68% percent of tumors were graded as grade 4, 21% as grade 3,
7% as grade 2, and 4% as grade 1. Fifty-three percent of these
tumors  were  immediately  adjacent to  the  major neurovascular
bundle of the extremity. Extremely large tumors or those in close
proximity to the neurovascular bundle were treated with neoad-
juvant chemotherapy or isolated limb perfusion (ILP) with TNF
and melphalan. Wide surgical excision was attempted in all cases.
Adjuvant radiation therapy was given when resection was per-
formed close to the neurovascular bundle or when marginal resec-
tion  (margins  of  less  than  1  mm)  or  less  were  performed.
Adjuvant chemotherapy was given to all patients who received
neoadjuvant chemotherapy or to those  patients  who presented
with large tumor prior to the introduction of the neoadjuvant pro-
tocol in 1995.
Results: Adjuvant chemotherapy was given to 22 patients and ILP
was executed in 24 patients. Surgery achieved wide margins in 78
patients, marginal margins in 28,  and radical margins in 11, in
seven of whom by an amputation. Adjuvant chemotherapy was
given  to  23  patients  and  radiation  therapy  to  77  patients.  All
patients were followed for at least 2 years (range; 27–97 months).
Sixteen patients (13.3%) had a local recurrence, occurring 3–30
months (median, 12 months) after surgery. Half of these recur-
rences occurred following wide excision. At most recent follow-up,
28 patients (23%) died of their disease.
Conclusions: The use of neoadjuvant chemotherapy given system-
ically or via ILP, attempted wide excision, and adjuvant radiation
and chemotherapy achieve low recurrence rate in deep soft-tissue
sarcomas of the extremities which are prone to high risk of recur-
rence.
Follow-up of 33 patients with mega-endoprothesis
O. Dubravko, S. Miroslav, K. Robert, O. Ivna1
(Department of Orthopaedic Surgery, University of Zagreb, School of
Medicine, and 1Public Health CENTRE, Zagreb)
Limb sparing surgery is a great challenge in contemporary oncol-
ogy, because the  reconstruction of the skeleton is performed in
patients  with  the  most  aggressive  bone  tumors.  From  1987  to
1999, at Department of Orthopaedic Surgery School of Medicine
University  of  Zagreb, special  modular uncemented mega-endo-
prostheses were implanted in 52 patients following ‘en bloc’ resec-
tion. Indications were: active and aggressive benign tumors (eight
patients, 15.4%); all types of malignant bone tumors (37 patients,
71.1%);  tumor-like  lesions  (three  patients,  5.8%);  massive
destruction of the proximal femur after severe war injuries or insta-
bility of standard hip endoprosthesis (four patients, 7.7%). Oste-
osarcoma was resected in 16  patients, Ewing sarcoma in eight,
chondrosarcoma in six, metastasis in two, fibrosarcoma, synovi-
osarcoma, periosteal osteosarcoma, MFH and leiomyosarcoma in
one  patient,  respectively.  Among  treated  patients,  28  (53.8%)
were females and 24 (46.2%) males. The youngest patient was an
11-year-old girl with osteosarcoma, and the oldest a 66-year-old
patient with chondrosarcoma. Salvage surgery of the hip joint was
performed in 25 (48.1%) and that of the knee joint in 27 (51.9%)
patients. ‘En bloc’ resection and salvage surgery of the knee joint for
the destruction of the distal femoral region and that of the proximal
tibia were done in 20 and seven patients, respectively. The median
length of the proximal femoral resection was 17 cm; of the distal
femur 16.4 cm; and of the proximal tibia 13 cm. The treatment
results were analyzed in 33 patients after five or more year’s of
follow-up. Of these 33 patients. 13 (39.4%) had died, two (6.1%)
disappeared because of the war situation, and 18 (54.5%) showed
no evidence of disease at the last follow-up. Three of 18 patients
have contracture of the knee joint, one patient has a fused knee
after salvage surgery, and a girl with active hepatitis and salvage hip
surgery  is  waiting  for  reoperation.  The  results  of  treatment
obtained in our patients with bone resection surgery and the mod-
ular  uncemented  mega-endoprosthesis  implantation  showed  a
good outcome. One major concern regarding tumor resection and
joint reconstruction with the special modular uncemented mega-
endoprothesis is the high price of the mega-endoprothesis.
Microsurgical  treatment  under  intraoperative
electrophysiological  nerve  monitoring  for  schwanoma
excision
F. Portabella, J. Casañas, M. Orduña, J. Serra1
(Orthopedics  Department  and  1Neurology  Department,  Ciutat
Sanitaria Bellvitge, Hospitalet Llobregat, Barcelona, Spain)
Methods: Schawanomas are nerve tumors characterized by slow
and solitary development. From 1996 to 1999, eight patients (four
male, four female) were surgically treated for nerve tumors. Age
ranges from 42 to 59 years old. Nerve tumors were localized in
median nerve (two cases), posterior tibial nerve (three cases), ulnar
nerve (one case) and brachial accessory nerve (two cases). Before
surgery nerve function was evaluated: muscular testing was nor-
mal, some patients present dysesthesia in ther region of the nerve,
and Tinel sign was positive on tumor localization. Nerve conduc-
tion studies was normal also. Diagnoses were done by IRM
Results: Microsurgical excision was performed under intraopera-
tive electrophysiological nerve monitoring in order to evaluate fas-
cicule  damage  during  surgery. Clinical  outcome  presents  Tinel
sign in the lesion site, and dysesthesia and allodynia persist for a
year. No tumor recurrences occur.
Conclusions: Although  schwanomas  are  infrequent  and clinical
nerve affectation is poor, surgery must be careful because nerve
damage  occurs,  so  microsurgical  technique  and  intraoperative124 Abstracts
electrophysiological  nerve monitoring are important  to  evaluate
nerve injury and nerve reconstruction.
The use of polyethylenterephtalate Trevira tube to improve
functional results in prosthetic reconstructive surgery after
bone tumour resection in the proximal humerus: clinical,
functional  and  radiographic  considerations  at  8  years
follow-up
M.A. Rosa, M. Galli, M. Tortora, G. Falcone & V. De Santis
(Orthopaedic Department, Catholic University, Rome, Italy)
Study and aim: Musculoskeletal tumour resection often requires
the sacrifice of important anatomical structures, with a consequent
functional deficit of the interested limb. There are many possibili-
ties  for  reconstruction  after  a  wide  resection  of  the  proximal
humerus. The authors report their experience using megaprosthe-
ses (modular or custom-made). A new system for the reconstruc-
tion of soft tissues, to obtain a good and fast functional recovery of
the involved limb, is also presented.
Methods: From January 1986 to 1999, 15 megaprostheses of the
proximal humerus were implanted at the orthopaedic department
of the Catholic University of Rome. All patients, seven males and
eight females, were affected with primitive or secondary (metas-
tases) malignant bone tumours with different histology. The pre-
operative planning was carried out using plain X-ray with a known
magnification, to establish the length of the prosthesis. CT scan
and MRI were useful to define the limits of the lesion and its exten-
sion.  Soft  tissue  reconstruction,  in  eight  cases,  was  performed
using a mesh (Trevira tube), dressed all along the prosthesis. The
patients were mobilized at the second post-operative day using an
external device for passive mobilization, and at the seventh post-
operative day they began active movements to strengthen the mus-
cular masses and to recover joint function. The functional results
were evaluated considering muscular strength, range of movement
and residual pain, and they were divided into good, fair and poor.
Results: At  a  medium  follow-up  of  2  years,  for  the  surviving
patients, we have obtained a good functional recovery of the artic-
ular movements. We evaluated the results dividing the patient into
two groups according to the level of bone resection (below or above
deltoid insertion). There were better functional results in patients
with resection above the insertion of the deltoid muscle. We have
not observed complications related to the prosthesis. In only one
case have we seen a probable intolerance to the Trevira tube.
Conclusions: The level of the resection is a main factor in order to
obtain a good functional recovery. The articular function depends
on the size of the resection. A wide resection (below deltoid inser-
tion) with the sacrifice of large muscular masses and of the osteoar-
ticular structures can represent a functional amputation. In our
experience  we  observed  that  the  use  of  modular  prostheses  in
reconstructive orthopaedic surgery is advantageous because of its
versatility,  compared to other reconstructive systems.  Moreover
the use of the Trevira tube, for easy anchorage of the myotendi-
nous structures,  allows a quick functional recovery offering  the
patients considerable advantages for their social life.
Uncemented conical femoral stem fixation in tumor TKA
K.A. Siebenrock & F.T. Ballmer
(Department  of  Orthopaedic  Surgery,  University  of  Berne,
Switzerland)
The principle of femoral stem fixation introduced by Wagner was
adapted to total knee replacement for bone tumors. Femoral fixa-
tion was obtained by an uncemented conical titanium alloy stem
with a coarse surface and eight sharp longitudinal ribs. Primary sta-
bility is achieved by the longitudinal ribs cutting into the cortical
bone,  and  secondary  stability  has  been  evidenced  by  osseous
ongrowth on the ribs. Preliminary experiences of this type of TKA
implanted minimally 6 years ago in tumor patients are reported.
The long conical femoral stem was connected to the original fem-
oral component of a semiconstrained GSB total knee revision pros-
thesis (Sulzer Inc., CH) by a standard 12/14-mm cone. The tibial
component was cemented in the usual manner. This type of pros-
thesis was used in three women and three men with a mean age of
36 years (7–75 years) over a 3-year time period. Distal femoral
tumors  included  central  osteosarcoma  in  four  cases,  recurrent
paraosseal  osteosarcoma  and  dedifferentiated  chondrosarcoma
each in one patient. Two patients died within 1 year after surgery
due to lung metastases. The four surviving patients had a mean
follow-up of 7.5 years (6–8.5 years) without evidence of tumor dis-
ease.  Bone  remodelling  and  a  continuous  solid  bone–implant
interface was observed in all cases without clinical or radiographic
signs of femoral stem loosening. Complications included rotational
instability of the cone attachment in two patients which required
surgical  correction.  During  the  same  surgery a  loose  cemented
tibial compent was revised in one of these patients. This type of
uncemented  conical  femoral  stem  fixation  for  TKA  in  tumor
patients has maintained clinical and radiographic stability after a
mean follow-up of 7.5 years. It seems promising and will be con-
tinuously used in our department. The cone system between the
conical stem and the femoral prosthetic component has been mod-
ified in the meantime.
The  role  of  salvage  operations  in  the  treatment  of  the
patients with the tumor of shoulder girdle
N. Trapeznikov, M.V. Sokolovsky & A. Amiraslanov
(N.N. Blokhin Cancer Research Centre, Kashirskoye sh.24, 115478,
Moscow, Russia)
The aim of the present  study is  an analysis of 75 patients with
tumor of shoulder girdle bones from 1992 to 1998. The males rep-
resented 50.7%  and the  females  49.3% of patients. The age of
45.4% of patients was from 14 to 30 years. In 68 patients (90.7%)
the tumor was localized in the humerus, and in seven (9.3%) in the
scapula. By the histological structure, the patients were distributed
into following groups: osteogenic sarcoma, eight patients; chond-
rosarcoma, 27 patients; parosteal sarcoma, six patients; giant cell
tumors,  20  patients;  MFH,  four  patients;  benign  tumors,  10
patients. The following operations were performed: resection of
proximal  part  of humerus  with  endoprosthesis  replacement, 22
patients (29.3%); interscapularis-pectoralis resection, 21 patients
(28%);  segmental  resections  with  autoplastics,  nine  patients
(12%); segmental resections with alloplastics, 11 patients (14.7%);
segmental resections without plastics, six patients (8%); marginal
resection, three patients (4%); excochelation tumor, three patients
(4%). Relapses were observed in 17 patients: in 27.3% after endo-
prosthesis replacement; in 69.7% after segmental resections with
auto- and alloplastics; in 19% after interscapularis-pectoralis resec-
tion. In eight (40%) of 20 patients treated by segmental resections
with  auto-  and  alloplastics,  post-operative  complications  were
observed: fracture and absorption of transplant. Thus, based on
the conducted investigation, we conclude the salvage operations
are indications for the treatment of shoulder girdle bone tumor.
‘Spontaneous regression’ of pulmonary metastases in three
patients with bone and soft tissue sarcomas
S.J. Strauss, A. McTiernan & J.S. Whelan
(The London Bone and Soft Tissue Service, The Middlesex Hospital,
Mortimer Street, London W1N 8AA, UK)Abstracts 125
Spontaneous regression of cancer is a rare phenomenon and very
few  cases  have  been  reported  in  bone  or  soft  tissue  sarcomas.
Three cases were seen at a single centre between 1992 and 1999.
Patient 1 presented with a retroperitoneal alveolar soft-part sar-
coma. A staging CT scan demonstrated an isolated lesion in the
right lung consistent with a pulmonary metastasis. Six months after
surgical excision and radiotherapy to the primary tumour, the lung
lesion became undetectable for 4 years. The patient then devel-
oped brain metastases. In patient 2, a CT scan demonstrated mul-
tiple pulmonary metastases 2 years after treatment for a localised
synovial sarcoma. The patient declined treatment and 3 months
later a CT scan showed a reduction in the size and number of nod-
ules. Follow-up is continuing. Patient 3 developed multiple pul-
monary metastases, demonstrated on CT scanning, 4 years after
surgery for a local recurrence of a Ewing’s  sarcoma. Follow-up
showed regression in a number of lesions and no progression in
others over a 2-year period. The patient died of unrelated causes.
Sarcomas are a heterogeneous group of tumours with variable nat-
ural histories but pulmonary metastases are invariably associated
with poor outcome. Histological confirmation was not obtained in
these  patients,  but  radiological  appearances are  consistent  with
metastases. The mechanisms for spontaneous regression remain
unclear, but the most cited cause is stimulation of host immunity
by, for example, surgery or infection. Patient 1 underwent surgery.
Alternative explanation is required for the other patients.
External fixation (EF) in pathological fractures (PF) of long
tubular bones
V.  Tepliakov,  S.  Tkachev,  G.  Matchak,  M.  Aliev  &  N.
Trapeznikov
(N.N. Blokhin Cancer Research Center, Kashirskoye sh. 24, Moscow
115478, Russia)
Purpose: To evaluate the role of EF in the treatment of patients
with PF.
Patients and methods: Between 1994 and 1999, the Ilizarov EF was
used for fixation an reposition of PF in 22 patients with primary and
metastatic tumours. There were 14F/8M, age 17–70 years. The dis-
tribution of cases according to histology was as follows: two patients
with Ewing sarcoma, three with lymphosarcoma, two with osteosar-
coma,  one  with  fibrous  osteodysplasy  and  one  with  malignant
fibrous hystiocytoma, eight with metastatic breast cancer, three with
metastatic renal cancer, one with melanoma and one with gastric
cancer. The location of PF was neck of femur in nine cases, proximal
femur in four, diaphysis femur in three, distal femur in three, neck of
humerus in one and humerus diaphysis in two. EF was performed
3–30 days (median 11) after PF. Angular deformation with extrem-
ity length discrepancy from 2 to 8 cm was observed in 12 cases. The
correction of PF was performed in 10 patients (six patients intraop-
eratively and four patients postoperatively).
Results: All patients were activated in 3–5 days after EF. Simultane-
ously, it was possible to administer local radiotherapy in 12 patients,
in two of them with intra-arterial chemotherapy and seven with sys-
temic chemotherapy. Six patients received hormone-, immuno- or
chemotherapy alone and four received no treatment. The definitive
PF consolidation was marked in 14 (64%) patients in periods from
173 to 372 days (average 171) after EF. After combined treatment
with  EF,  three  patients  underwent  delayed  bone  resections  and
reconstruction  with  endoprosthesis,  allograft  and  vascularised
autograft. At median follow-up of 21 months, the functional results
were excellent in 10 (64%), good in four and satisfactory in three
(14%). All patients have had acceptable life quality, irrespective of
disease course. Five patients (23%) died from disease during the first
year of follow-up.
Conclusion: EF  permits  to  obtain  a  rigid  fixation  of  PF,  early
activation of the patients and satisfactory conditions for combined
treatment administration. In selected cases it is possible to perform
delayed limb-salvage procedures.
Clinical  and  radiological  findings  in  classical
chondrosarcoma  with  emphasis  on  a  simple  and
reproducible grading system
H. Welkerling1, S. Kratz2, G. Delling3 & V. Ewerbeck2
(1Departement  of  Orthopaedic  Surgery,  University  of  Graz,
2Departement of Orthopaedic Surgery, University of Heidelberg, and
3Departement of Osteopathology University of Hamburg, Germany)
Study: 35  chondrosarcomas (CS) and 16 enchondromas (EC)
were analyzed in a retrospective study.
Aim: The  purpose  was  to  verify  whether  a  correlation  exists
between the grading (Welkerling et al., 1996), recurrence rate, and
radiological and clinical findings.
Methods: 35 patients with CS and 16 patients with EC, both with
complete  documentation,  were  managed at  the  Department  of
Orthopaedic  Surgery  of  Heidelberg  University.  The  study
included X-ray analysis, histological analysis, grading (based only
on nuclear size and nuclear polymorphism) and evaluation of clin-
ical data. EC were separated from low grade CS by growth pattern
(Mirra, 1989).
Results: The  mean  age  was  50  years;  6%  of  all  lesions  were
located in the trunk and 46% in the long bones. The mean follow-
up time was 40 months; 51% of the lesions were grade 1, 31%
grade 2 and 17% grade 3; 91% of the patients with CS (88% of
grade 1 CS) reported pain compared to only 44% with EC. Local
recurrence was observed in 26%. Metastasis occurred only in one
patient (grade 3 CS). All except one of the grade 3 tumours had
local recurrence; 91% of the lesions were locally destructive, and
in 57% an extraosseous component could be observed. No local
recurrence was observed in Lodwick’s grade I lesions. All of the
grade 3 CS were classified Lodwick’s grade II or III as well as 80%
of the grade 2 CS; 85% of the CS and 82% of grade 1 lesions had
blurred calcifications in comparison to only 19% of the EC cases.
Cortical destruction could be observed only in 19% of EC, but in
94% of grade 1 CS. None of the EC lesions had an extraosseous
component, whereas 47% of grade 1 CS did. Histologically there
was no significant difference between the presence of double nuclei
in EC (88%) and CS (94%). No difference of studied cytological
features could be observed between grade 1 CS and EC.
Conclusions: The reproducible and simple grading system (Welk-
erling et al., 1996) correlates with the frequency of local recurrence
and radiological appearance. The radiological findings of grade 2
and 3 tumours were much more aggressive in comparison to grade
1 lesions. An extraosseous component could be found more fre-
quently in grade 2 and 3 CS. EC and grade 1 CS are distinguishable
by growth pattern, but not by cytological features. Cortical destruc-
tion could be observed more frequently in grade 1 CS and the pres-
ence of an extraosseous component and blurred calcifications are
suspicious of malignancy in differentiation of EC and low grade CS.
Internal  hemipelvectomy—a  less  mutilating  form  of
operational treatment of bone malignancies in children and
youth
W.  Wozniak,  M.  Rychlowska-Pruszynska,  M.  Kuczabski,  T.
Izbicki,  T.  Walenta,  A.  Szafranski,  K.  Bilska,  M.  Lorkowska-
Precht & J. Kijowski
(Clinic of Oncological Surgery in Children, National Research Institute
of  Mother  and  Child,  Kasprzaka  str.  17  A,  PL  01-211  Warsaw,
Poland)
In the period of 1985–1999 more than 250 patients with primary
bone malignant tumours (osteosarcoma, Ewing sarcoma, chondro-
sarcoma) were treated in the National Institute of Mother and Child
in Warsaw. In all of them contemporary methods of complex treat-
ment were applied, including chemotherapy, surgery and/or radio-
therapy. Localisation of primary neoplasm focus in the pelvis is less
common and the radical surgery is problematic. We present a group
of 13 patients in whom following operations were performed: two126 Abstracts
‘classical’ hemipelvectomies (excision of pelvis bone with exarticu-
lation of lower extremity); 11 internal hemipelvectomies (excision of
pelvis bone sparing the lower extremity: two patients, type I, hip
bone ala excision above the hip articulation; one patient, type II A,
excision of the hip bone ala with the hip articulation; two patients,
type II B, ischiadic and pubic bone excision with the hip articula-
tion; four patients, type II C, excision of the hip bone ala with the
hip articulation, pubic and ischiadic bones; two patients, type III,
pubic and ischiadic bones excision under the hip articulation. Inter-
nal hemipelvectomies have been made mainly in the last 2 years.
Ten patients are alive with a follow-up of 8–48 months. The patients
have been rehabilitated with regard to the salvaged limb.
Conclusions: (1) The internal hemipelvectomy is a less mutilating
operational treatment, performed within the complex therapy of
malignant bone tumours in children and youth. (2) The internal
hemipelvectomy  allows the  limb  salvage and is  efficacious with
regard  to  patient’s  walking.  (3)  The  internal  hemipelvectomy
requires a very well prepared operation team, good technical back-
ground allowing reconstruction of the resected bones and rehabil-
itation in the postoperational time.
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Protocol  of  pre-  and  post-operative  nursing  of  patient
treated  by  resection  and  prosthetic  reconstruction  of  the
knee for bone tumors
S. Urrai, P. Ruggeri & S. Mini
(Istituto Ortopedico Rizzoli, Bologna, Italy)
The aim of this paper was to define the protocol of pre-operative
and post-operative nursing applied in the Surgical Department of
Orthopedic Oncology at the Istituto Rizzoli for patients treated by
knee resection for bone tumors and reconstruction with modular
uncemented  prosthesis  (HMRS  prosthesis).  A  series  of  435
patients treated between 1982 and 1997 were reviewed, including
324 cases of resection of the distal femur, 106 of the proximal tibia
and five of extrarticular resection of both distal femur and proximal
tibia (removed ‘en-bloc’). There were 249 males and 186 females,
whose age ranged from 5 to 68 years. Most frequent histological
diagnoses were  osteosarcoma  (276  cases), chondrosarcoma (31
cases), Ewing’s sarcoma (18 cases) and malignant fibrous histiocy-
toma (25 cases). Most of the lesions were staged II B. All our nurs-
ing  forms  were  reviewed  for  all  these  patients.  A  remarkable
change was observed over the years in nursing procedures for such
patients, namely related with an increasing experience in the man-
agement of  complications.  Our  nursing protocol  is  reported  as
defined at present and currently in use in our Surgical Department
for  these  patients.  This  protocol  is  divided  into  the  following
phases: pre-operative preparation of the patients; immediate post-
operative nursing of the patient (first 12 h); post-operative nursing
of the patients and beginning of functional rehabilitation.
The  protocolization  of  nursing  care  as  a  measure  to
diminish complications in the use of ‘implanted port’
P. Miqueleiz, C. Echarri, A. Belen Muñoz, S. Pérez & E. Marín
(Paediatric Ward, University Clinic of Navarra, Pamplona, Navarra,
Spain)
Since the year 1983, the pediatric department of the CUN uses the
‘implanted port’ as a means of reaching the venous tract in children
with onco-hematoligical diseases. A series of complications have
been found derived from the use of this system in both the bibliog-
raphy studied as well as through experience, principally obstruc-
tions and infections. A protocol of nursing activities was elaborated
based on a comparative study to demonstrate that the complica-
tions can be diminished by means of its application. The compar-
ative  study  of  this  protocol  is  presented  with  the  purpose  of
demonstrating its effectiveness.
Has chemotherapy in young patients with osteosarcoma any
impact on weight?
C.  Forni,  L.  Loro,  T.  Mazzei,  C.  Beghelli,  M.  Tremosini,  A.
Biolchini,  P. Simoni,  A.  Treggiani, E. Dandolo, L.  Loro & T.
Coccia
(Servizio di Chemioterapia degli Istituti Ortopedici Rizzoli, Bologna,
Italy)
The aim of this study was to evalutate in a period of 9 months how
chemotherapic drugs affect weight in patients with osteosarcoma
of  the  extremity  treated  with  neoadjuvant  chemotherapy  (HD
MTX, ADM, IFO, CDP). The weight of 237 patients was moni-
tored at the beginning, during and at the end of therapy between
January 1993  and November 1998. The response to antiemetic
therapy was contemporarily monitored in order to evaluate a pos-
sible relationship with both weight loss and emesis. At the end of
the  therapy  60.8%  of  patients  showed  a  weight  increase  of
10.9±7.2%, 33.3%  a  loss  of  7.6±5.3%  while  with  5.9%  of  the
patients no variation was recorded. The weight increase resulted
proportional to both therapy duration (p=0.04)  and number of
cycles (p=0.003). No relation could be noticed between weight
variation and characteristics of patient (sex, age, origin, lesion site,
kind of performed protocol and incidence of emesis). In conclu-
sion, we observed that opposite to the commonly accepted opinion
that chemotherapy leads to weight loss with these patients and with
this  chemotherapic  protocol,  the  majority  of  patients  showed a
weight increase. It is possible that these results can be referred to
different  factors  such  as  cognitive  distraction,  autonomous
kitchen, etc.
Nursing process in order take care of children and teenagers
affected by osteosarcoma
M.J. Lleo, M. Remiro, I. Irigoyen, D. Colunga & P. Lacasa
Malignant tumours of bone account for about 5.6% of the malig-
nant tumours in children and teenagers, and they also represent
0.5% of all malignant tumours which affect humans. In the Uni-
versity  Clinic  of  Navarra,  osteosarcoma  has  been  treated  since
1972. The multidisciplinary treatment of this kind of disease with
chemotherapy, surgery and RIO, has posed a challenge for nurses.
Therefore, and basing this study on the acquired experience, we
propose a new nursing process in order to take care of children and
teenagers who are affected by osteosarcoma.
The  evaluation  of  a  specialist  teenage  cancer  unit  using
ethnography
S. Pearce, D. Kelly & A. Mulhall
(UCL Hospitals NHS Trust)
This presentation will illustrate the ‘insiders’ view of the culture of
one of  the  few specialist  adolescent oncology units  in the  UK.
Cancer during the teenage years brings with it the challenges of
cancer superimposed on the normal developmental transitions of
adolescence. A growing literature points to the need for specialist
expertise and services for teenagers and their families with cancer.Abstracts 127
Despite this there is little research evidence to support the organi-
sation of such services. The study used ethnography to evaluate a
teenage  cancer  unit.  This  involved participant  observation, the
immersion of a researcher in the culture of the unit, together with
in depth interviews of 10 parents, 10 teenagers and 16 members of
the  unit’s  interdisciplinary  team.  The  study’s  collaborative  and
reflexive nature has been paramount. The field notes and the inter-
view transcripts have been analysed to identify recurring themes.
These include: the physical structure of the unit in terms of main-
taining privacy, space and normality; the structure and rituals of
the day; and the feelings of it being home. As one participant states
‘… it’s almost like a second home … unfortunately’. The language
and the culture of cancer, the shared experience of being on the
unit, together the individual experience of teenage cancer have also
emerged as key themes from the data. This is the first study evalu-
ating this specialist  area in the  UK.  The findings will  add to a
sparse literature, stimulate the development of specialist practice
and provide  direction  for  the  future  organisation  of  adolescent
oncology service provision.
Nursing  care  in  patients  treated  with  internal
hemipelvectomy for bone tumors
S. Mini, S. Urrai, D. Donati & M. Mercuri
(Orthopaedic  Oncology  Unit,  Istituto  Ortopedico  Rizzoli,  Bologna,
Italy)
In the Rizzoli Oncology Unit a number of surgical procedures for
pelvic tumor are routinely applied. Internal hemipelvectomy and
reconstruction due to malignant bone tumors are the most difficult
to  follow in  terms  of  nursing  care.  Bed  positioning, indwelling
catheters  (i.v.,  intra-cardiac,  sondino  nasogastric,  bladder) and
draining tube care, different therapy administration, requests for
tests are only some of the main nursing activities. A retrospective
study to measure the impact of nursing care in these patients has
been addressed.
Material: From January 96 to December 99, 34 patients under-
went internal hemipelvectomy with disruption of the pelvic ring.
Ages ranged from 10  to 59 years (average 34). Fifteen patients
were male and 19 female. The diagnosis was chondrosarcoma in
15 cases, osteosarcoma in 10, Ewing’s sarcoma in five, GCT in
two,  leiomyosarcoma  and  synovial  sarcoma  in  one  each.  The
tumors were mainly located in the sacroiliac region in 11 cases
(Group A), while the anterior arch was affected in another seven
cases (Group B) and the hip area in the remaining 16 cases (four
of which were located in the whole hemipelvis; Group C). Major
reconstruction as allografts or prosthetic devices were applied in 22
cases, while the other 12 patients achieved no or minor reconstruc-
tion.  The  pre-operative  check-up  reported  no  significant  data;
however, in  22  patients  a mean  of  six  blood  autoinfusion sacs
(from one to 20) were collected  to supply the estimate  surgical
blood loss.
Results: A number of parameters have been followed during the
study. Some of which, such as fever control, blood tests (count,
clot) indwelling catheter care, antibiotic,  antipain medications,
anti-thrombotic therapy, motility  of the foot, dermal sensitivity
and blood circulation control, and bed positioning were included
in a protocol. The nursing care associated with internal hemipel-
vectomy patients resulted as one of the most time-consuming due
to the magnitude of the operation and related needs. According
to the type of operation the nursing activity can be more complex;
the group of anterior pelvic arch resection showed longer hospital
stay,  more  difficult  following  of  evacuation,  bladder  catheter
management and wound dressing, while in hip reconstruction the
use of a spica cast is the rule. This study would be only a first step
in reviewing the nursing care impact in different types of opera-
tions. More appropriate patient data collection forms will be nec-
essary to correctly note all the patient care related activity and,
hence, better evaluate the real complexity of the nursing occupa-
tion.